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Inge van der Weijden
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General introduction
Introducing the Insulin-like Growth Factor-1 Receptor
Insulin-like growth factor-1 (IGF-1) and its receptor, the insulin-like growth factor-1 
receptor (IGF-1R), are signal transducing elements in one of the most crucial cellular 
pathways in life. In conjunction with insulin and growth hormone (GH), they regulate 
protein synthesis, glucose metabolism, cellular proliferation and differentiation, which 
are fundamental to development and sustenance of living organisms. GH, insulin and 
IGF-1, jointly referred to as the ‘somatotropic axis’, play a pivotal role in the regulation 
of organism growth, metabolism and aging. IGF-1 signaling has consequently been 
coupled to a myriad of biological processes in animals and humans. For example, in 
honey bees, a key protein of the insulin/insulin-like system (Insulin receptor substrate, 
IRS) influences the development of female larvae into either queen bees or worker 
bees, which determines their lifetime fate to reproduce or to forage for food [1]. 
Also, changes in IGF-1 levels in hibernating squirrels are thought to contribute to 
the phenomenal survival and prevention of muscle loss under the extreme catabolic 
conditions of hibernation [2,3]. 
Of particular interest is the contribution of IGF-1 signaling to longevity. The 
somatotropic axis regulates growth and development of the young immature organism, 
but paradoxically later in life becomes involved in the process of aging itself [4]. Caloric 
restriction, which causes down-regulation of the IGF-1 pathway, is known to extend 
lifespan in worms, flies, mammals and humans. Also, rodent as well as human dwarfs 
(Laron syndrome), exhibiting reduced GH secretion or a resistance to GH and a 
subsequent decline in IGF-1 signaling, are short in stature, but live long [5]. Moreover, 
they are less frequently diagnosed with cancer. In animal models, a causal relationship 
between IGF-1 levels and tumorigenesis has been confirmed, as IGF-1 deficient mice 
show reduced growth and metastasis of tumours and xenografts and increased resistance 
to carcinogen-induced tumorigenesis [6]. Vice versa, transgenic overexpression of IGF-
1 in basal epithelial cells induced hyperplasia and well-differentiated adenocarcinomas 
[7].
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A Short Scientific History of the Insulin-like Growth Factor-1 Receptor
As early as December 1976, a PNAS paper recognizes that the insulin/insulin-like 
system is involved in growth of breast cancer cells [8]. This paper strikingly displays 
how basically the same issues at that time, such as the interaction with steroid 
hormones, play a role today. The paper reported on growth stimulation by insulin 
in an at that time recently characterized hormone responsive breast cancer cell line 
MCF7 (we use that ‘same’ cell line in the experiments of this thesis), and stated: “The 
mechanism of action of insulin and its interaction with other hormones in target 
tissues are poorly understood. Binding to the cell membrane is thought to be the first 
step in insulin action, followed by stimulation of an unknown effector system, which 
in turn stimulates a variety of cell metabolic pathways. Since other peptide and steroid 
hormones may influence or modulate these same pathways, it is obvious that one must 
consider these complex interrelationships in studying the mechanisms of action of any 
of these hormones” [8]. Certainly, the ‘unknown effector system’ and the ‘cell metabolic 
pathways’ have been unraveled in great detail in the decades that followed. However, 
the ‘complex interrelationships’ with other peptide and steroid hormones have not 
yielded every bit of complexity up till today. 
Insulin like growth factor itself was recognized as an important growth factor for T47D 
breast cancer cells in 1984 [9]. Five years later, the IGF-1R, initially known as the type 
1 somatomedin receptor, was specified and identified in breast tumor biopsies [10]. 
Moreover, successful experimental blockade of the receptor by a mouse monoclonal 
antibody (alpha-IR3) followed [11,12]. Xenogenecity of the murine antibodies, 
however, frustrated implementation of antibodies into clinical therapies until genetic 
engineering techniques enabled the construct of humanized therapeutic antibodies 
in the nineties [13]. Over the next decade, treatment with the anti-HER2-antibody 
trastuzumab combined with cytotoxic drugs resulted in revolutionary clinical benefit 
in patients with prognostic unfavourable local or advanced HER2-overexpressing 
breast cancers [14-16]. Trastuzumab is now a standard part of adjuvant and palliative 
therapeutic options in HER2-overexpressing breast cancers. Accumulating evidence 
suggesting that monotherapy with a target-specific drug was insufficient to address 
frequently occurring tumor reliance on more than one defective or interacting signaling 
pathway, renewed the scientific and clinical interest in IGF-1R as a potential new 
and adjunctive anticancer target in the early 21th century [17]. This coincided with 
the introduction of small molecule drugs in oncology, which, unlike antibodies, act 
directly on intracellular transducing proteins or intracellular signaling proteins coupled 
to receptors. A successful example is imatinib, which inhibits mutated c-kit and is an 
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important drug in the treatment of gastrointestinal stromal tumors. So, at the time of 
onset of this study not only IGF-1R targeted antibodies, but IGF-1R tyrosine kinase 
inhibitors as well, were being developed [18-21]. 
Translational challenges of IGF-1R targeted drugs 
Within the setting of ongoing pre-clinical and early clinical development of IGF-
1R targeted therapy, little was known at the start of this study about which tumors 
would respond to IGF-1R directed therapy and which patients would benefit. IGF-
1R signaling was shown in a wide variety of tumors, but positive amplification and 
conclusive correlations with clinical or pathological parameters were not prevailing. 
Also, a growing body of evidence showed the IGF-1R to be a team player in a well-
organized line-up of growth factor receptors and proliferation-signal transducing 
molecules, in breast cancer including among others HER2, EGFR, estrogen receptors, 
and eventually insulin receptor. Targeting any single of these receptors might therefore 
not suffice to halt tumor progression in the long term. 
Moreover, the body-wide physiologic function of IGF-1R and interactions with the 
metabolic function of closely related insulin receptor (IR) theoretically jeopardizes 
efficiency and tolerability of IGF-1R inhibitors. Originating from a putative same 
ancestor gene, the IGF-1R has specialized more in cell growth and anabolic functions, 
whereas the insulin receptor merely regulates metabolism, but they share a very similar 
molecular architecture and physiologically they still have functional overlap [22]. 
Diabetic complications were therefore anticipated. 
Aim of the Thesis
We set out to determine clinical indicators of IGF-1 dependency and responsiveness to 
IGF-1R targeted therapy in breast cancer in two large cohorts of breast cancer patients 
and a set of three breast cancer cell lines. The first cohort included 429 female patients 
treated for a primary local or locally advanced invasive ductal breast carcinoma at the 
University Medical Center Groningen between January 1996 and December 2005. 
Of these tumors, tumor material was available for IGF-1R, ER, HER2 and EGFR 
immunohistochemistry and patient, tumor characteristics and data on follow-up were 
available from hospital records. Patients included in the second cohort participated 
in a study based in Northern Netherlands and designed to investigate low-penetrance 
genetic mutations predisposing to breast cancer. Of 584 patients in this study plasma 
samples, clinical outcome parameters and (self-reported) life-style and reproductive 
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factors were available to study associations with IGF-1 and IGFBP-3 plasma levels. In 
laboratory experiments, effects of treatment with an IGF-1R tyrosine kinase inhibitor 
were tested in breast cancer cell lines MCF7, SKBR3 and T47D, representing different 
clinical subtypes of breast cancer. The SKBR3 cell line represents HER2-overexpressing 
breast cancer. MCF7 and T47D represent luminal A and B hormone receptor-positive 
breast cancer, respectively. 
Outline of Thesis
In our review in chapter 2, we discuss how the specialized functions of IGF-1R and 
IR are regulated by structural homogeneity, diverging affinities and regulatory IGF 
binding proteins within in a ligand-activated receptor-signaling system. Furthermore, 
an overview is presented of anti-tumor effects that could be accomplished by IGF-1R 
targeting drugs and potential applications in various tumor types. Some of the initial 
hesitations to develop IGF-1R targeting drugs for clinical use have been overcome, 
but the clinical and biological correlates of IGF-1R response in tumors need special 
attention in the context of a highly versatile receptor system and interactions with 
other peptide and steroid hormone receptors. 
One of the prerequisites of targeted therapy is an identifiable measure of 
responsiveness of the tumor to the drug. In chapter 3, IGF-1R expression measured 
by immunohistochemistry was investigated in a consecutive cohort of patients with 
invasive ductal carcinomas of the breast and related to patient and tumor characteristics, 
molecular markers, and prognosis. IGF-1R targeted therapy in breast cancer is 
particularly interesting, because enhanced therapeutic effects have been demonstrated 
combining IGF-1R targeted drugs with tamoxifen and trastuzumab in vitro and in 
vivo [23,24]. Cell line studies suggest IGF-1R-signaling has different effects on cellular 
behaviour like proliferation and migration in ER-negative tumors as opposed to 
ER-positive tumors. In hormone responsive breast cancer cell lines IGF-1R and ER 
synergistically stimulate proliferation, but in the absence of ER, IGF-1R activation 
fails to induce mitogenesis, while its migratory actions are preserved [25]. In our 
patient cohort we sought to confirm divergent effects of insulin-like growth factor-1 
receptor expression on prognosis in estrogen receptor positive vs. estrogen receptor 
negative tumors. At the other extreme of the spectrum of breast tumors, IGF-1R 
directed therapy might make a difference in triple negative tumors. Defined by absence 
of estrogen receptor, progesterone receptor and HER2 expression, these tumors have 
a worse prognosis and lack scaffolds for any conventional targeted treatment up till 
now [26]. Accordingly, the relatively small subgroup of triple negative tumors in the 
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present cohort was studied in more detail and in order to obtain more statistical power, 
we combined these data with a separate dataset of triple negative tumors with similar 
clinico-pathological parameters.
Most attention is drawn to autocrine effects of the IGF-1 system in cancer, which is 
certainly justifiable. However, endocrine effects of IGF-1 may as well play a role in the 
prognosis of breast cancer. Circulating IGF-1 levels are by now firmly established as 
a risk factor for developing breast cancer, markedly in estrogen positive tumors [27]. 
More importantly, an IGF-1 activated gene transcription signature has been defined 
and in breast cancer this transcription profile was connected to poor prognosis in ER 
positive tumors [28]. These data suggest that circulating IGF-1 could locally act on 
tumors by activating gene transcription programs leading e.g. to tumor progression 
or hormone independence. Therefore, we aimed to explore the effect of IGF-1 and 
IGFBP-3 plasma levels on prognosis in a large cohort of breast cancer patients. 
Blood sample collection and storage in large population-based or multi-centre studies 
involve complex logistics, frequently requiring concessions to most optimal conditions 
for sample processing. The use of different blood specimens and the duration of the 
blood processing delays vary much among large multi-center studies. Hence, we 
assessed restrictions in blood processing delays for IGF-1 and IGFBP-3 measurements 
in EDTA plasma, heparin plasma and serum samples, respectively. This study, described 
in chapter 4, ascertained valid measurements of IGF-1 and IGFBP-3 levels in available 
plasma samples. Results of IGF-1 and IGFBP-3 plasma levels in breast cancer patients 
and correlation with overall survival and occurrence of second primary breast tumors 
are presented in chapter 5. 
Chapter 6 outlines responses to the IGF-1R specific tyrosine kinase inhibitor NVP-
AEW541 in different clinical subtype breast cancer cell lines, expressing contrasting 
levels of estrogen receptor, HER2 and IGF-1R. Tyrosine kinase inhibitors (TKI) are 
small-molecule agents that block active kinase domains at the cytoplasmic domain of 
cell-surface receptors and are generally considered less specific compared to monoclonal 
antibodies. Apart from different toxicity profiles, TKIs may inhibit several signaling 
pathways, which could rather be beneficial in tumors depending on more than one 
overexpressed or defective target [29]. Also, effects of TKIs in combination with 
cytotoxic drugs may differ from anticipated results based on similar combinations with 
antibodies. We tested response to NVP-AEW541 in combination with conventional 
systemic drugs and studied changes in cellular signaling networks downstream of the 
IGF-1R. 
In chapter 7 we summarize our data and debate if and how the results of this thesis 
may contribute to future developments.
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The insulin-like growth factor 1 receptor 
in cancer: Old focus, new future
Abstract
The importance of insulin-like growth factor 1 receptor (IGF-1R) signalling in 
malignant behaviour of tumour cells is well established. Currently, development of drugs 
targeting the IGF-1R as anticancer treatment is emerging. Several IGF-1R targeting 
strategies are being investigated in phase I and phase II clinical trials. Interactions of 
IGF-1R with insulin receptor, however, might complicate efficiency and tolerability 
of such drugs. This review describes mechanisms, recent developments and potential 
limitations of IGF-1R antibodies and tyrosine kinase inhibitors.
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Introduction
A new class of drugs targeting the insulin-like growth factor receptor type 1 (IGF-1R) 
is in an advanced stage of clinical development. The choice of this receptor tyrosine 
kinase (RTK) as a target for anticancer therapy is driven by a multitude of in vitro 
and in vivo data supporting a powerful pro-survival signal of this receptor in tumour 
growth and development. In general, RTKs execute key roles in tumour progression 
and therefore represent attractive targets for anticancer therapy [1]. Indeed, since the 
introduction of imatinib in the treatment of chronic myeloid leukaemia and GIST in 
2000, RTK targeting has successfully been applied in the treatment of various other 
tumour types as well (for a review, see Ref. 2). 
The IGF-1R is different from most RTKs regarding some structural features, receptor-
ligand interaction and down-stream signalling. While most RTKs are mainly involved 
in autocrine and paracrine cell-to-cell signalling, IGF-1R signalling is also under 
endocrine control [3]. IGF-1R activation by insulin-like growth factor 1 (IGF-1) 
effectuates the growth stimulating effects of growth hormone (GH) in the target organs. 
Moreover, IGF-1R signalling is intimately connected to the metabolic functions of 
insulin. Due to the ubiquitous presence and body-wide physiologic function of IGF-
1R, targeting its signalling may result in serious side effects. Especially interactions 
with the metabolic function of the insulin receptor (IR) need special attention.
This review aims to explore which anti-tumour effects could be accomplished by IGF-
1R targeting drugs and potential limitations of such drugs, considering the mechanistic 
basis of IGF-1R function in normal physiology and cancer. We will discuss recent 
developments, which show that some of the initial hesitations to develop IGF-1R 
targeting drugs for clinical use have been overcome. In addition, several potential 
applications of IGF-1R antibodies and tyrosine kinase inhibitors in various tumour 
types and in combination with conventional therapy will be described. 
Structure and physiological function of the IGF-1R
The IGF-1R functions as a heterotetramer of two extracellular ligand-binding 
α-subunits and two β-subunits comprising the transmembrane and tyrosine kinase 
domains [1]. Upon ligand binding a conformational change induces activation of the 
kinase. Several docking proteins, such as Src-homology 2 domain-containing (Shc) 
protein and insulin receptor substrates (IRS1–4), are subsequently recruited to the 
phosphorylation sites in the cytoplasmic domain. Then the signal is propagated via the 
phosphatidylinositol-3-kinase (PI3-kinase)/Akt and mitogen-activated protein (MAP) 
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Figure 1. Schematic Illustration of the IGF-1R and Downstream Pathways (P, phosphorylation site; 
IRS, insulin receptor substrate; MAPK, mitogen-activated protein kinase).
kinase pathways resulting in cell proliferation and inhibition of apoptosis. 
IGF-1R signalling can also induce differentiation, malignant transformation and 
regulate cell–cell adhesion (Fig. 1). A dynamic downstream signalling network of 
different phosphorylation sites of the receptor and cell-context specific recruitment 
and activation of signalling molecules regulates these different functions [4]. For 
example, while the tyrosine kinase domains are indispensable for all receptor functions 
and stimulate mitogenicity and motility of cells, phosphorylation at other cytoplasmic 
tyrosine residues confers additional capability for anchorage-independent growth and 
increases metastasising capacity of tumour cells [5]. More downstream, activation of 
docking protein IRS-1 favours proliferation while suppressing differentiation, whereas 
IRS-2 is involved in motility [6,7]. Furthermore, the IGF-1R can interact with steroid 
hormones and their receptors, other peptide growth factor receptors, extracellular matrix 
proteins, integrin receptors and cytokines, such as transforming growth factor-β[3].
The IGF-1R functions in a ligand-activated receptor-signalling system with the insulin 
receptor (IR) (Fig. 2). The IGF-1R is highly homologous to both splice variants of the 
IR (IR-A and IR-B), particularly in the cytoplasmic domain [8], and these receptors 
use signalling pathways much similar to the IGF-1R [9]. The structural homogeneity 
allows formation of hybrid receptors (hybrid-R) in which an IGF-1R αβ-chain is 
connected to an IR-A or -B αβ-chain. When IGF-1R and IR are co-expressed on 
the same cell, receptor hybrids form by random assembling and the least abundant 
receptor is drawn predominantly into hybrid-Rs [8]. The third receptor in the system 
is the IGF-2 receptor (IGF-2R), which is structurally and functionally unrelated to the 
IGF-1R and IR. The IGF-2R has no known signal transducing function, but it has a 
regulatory role in the IGF-1R system by degradation of IGF-2 [3]. 
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Figure 2. The Ligand-Activated Receptor Family of IGF-1R and IR. Schematic representation of 
ligands, receptors and regulatory binding proteins (IGFBPs). The situation of IR is depicted as for IR-A, 
the isoform with most functional overlap with the IGF-1R. In contrast to IR-B, IR-A binds IGF-2 and 
can perform IGF-like functions.
IGF-1 is the principal ligand for the IGF-1R and hybrid-R. While IGF-1 and insulin 
are able to activate each other receptor only at high concentrations, IGF-2 is special in 
that it can bind the IGF-1R as well as the hybrid-R and IR-A with affinities approaching 
that of the cognate ligands [10]. It is intriguing how IGF-1R and IR can accurately 
perform distinct cellular and physiological functions despite a very similar molecular 
architecture. IGF-1R and IR, however, do share some functional capabilities, IR-A 
can perform IGF-like functions and IGF-1R could partially compensate for loss of 
metabolic functions of the IR [11]. These functional similarities and dissimilarities 
are reflected in receptor expression and ligand availability. Both IGF-1R and IR are 
almost ubiquitously expressed, enabling a close connection. However, IR expression 
prevails in metabolic target organs, such as the liver, where IGF-1R levels are absent, 
while IGF-1R expression is high and IR low in e.g. fibroblasts [8]. Also, although 
the ligands share some similar affinities for receptor binding, the regulation of ligand 
bioavailability differs fundamentally. Insulin is under tight control of blood glucose 
levels and is excreted by the pancreas solely in periods of rising blood glucose levels. 
IGF-1 is produced under endocrine GH control in the liver as well as in somatic cells. 
In contrast to insulin and IGF-1, production of IGF-2 is autocrine and paracrine. A 
group of 6 IGF binding proteins (IGFBPs) tightly regulate stability of IGF-1 and IGF-2 
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in the circulation, transport to target tissues and interaction with the receptors, thereby 
preventing unlimited availability of IGF-1 and -2 to activate the receptors. Besides 
the regulatory effects on IGF-1 and -2 functions, IGFBPs exhibit IGF-independent 
actions, such as growth inhibition and apoptosis [3]. In normal physiology, IGF-1R 
stimulates linear body growth, promotes neuronal survival and myelination, postnatal 
mammary development and lactation, and is implicated in bone formation and renal 
function [3]. 
The IGF-1R plays a central role in integrating signals of nutrition and stress into energy 
shifts from energy-expensive anabolic processes, such as growth and reproduction, to 
preserving responses under catabolic circumstances [12] (Fig. 3). In conclusion, the 
body-wide expression and availability of IGF-1 and IGF-1R and interaction with 
IR and other signalling pathways are fundamental for its role in the organism. The 
implication of targeting a receptor that is ubiquitously expressed in normal tissues 
throughout the body, though, has long been a serious concern.
IGF-1R in cancer
The challenge of the last two decades has been to define the exact contribution of IGF-
1R to growth and development of a wide range of malignancies and to identify the 
therapeutic potential of targeting this receptor as anticancer therapy. The involvement 
of the IGF-1R in malignant transformation was first recognised in fibroblasts derived 
from homozygous IGF-1R null mice embryos [13]. Mouse embryo fibroblasts are 
prone to transformation; however, in the absence of IGF-1R they become resistant to 
malignant transformation by a number of oncogenes (e.g. Simian Virus 40T antigen 
(SV40T), Ewing Sarcoma fusion protein). Re-expression of the IGF-1R restored 
susceptibility to transformation in these cells. Animals with homozygous knockout 
of the IGF-1R die at birth due to poor organ development [14]. Therefore, in vivo 
effects of decreased IGF-1R signalling on tumour growth have been studied in IGF-1 
deficient mice. Low IGF-1 levels were associated with reduced growth and metastasis of 
tumours and xenografts and increased resistance to carcinogen-induced tumourigenesis 
[15]. Vice versa, transgenic overexpression of IGF-1 in basal epithelial cells induced 
hyperplasia and well-differentiated adenocarcinomas of skin and prostate [16,17]. In 
population studies, high serum levels of IGF-1 have been associated with an increased 
risk on prostate cancer and premenopausal breast cancer [18]. And increased incidence 
of colorectal adenomas and cancer is seen in acromegaly, in which hypersecretion of 
GH is accompanied by elevated IGF-1 levels [19]. In vivo overexpression of IGF-1R 
accelerated the development of tumours in a mouse model of cancer (RIP1-TAG2) 
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[20]. In this mouse model, expression of oncoprotein SV40T in pancreatic islet β 
cells leads to tumour formation, which is characteristically accompanied by IGF-2 
upregulation, providing an activating ligand for the IGF-1R. Remarkably, IGF-1R 
overexpressing RIP1-TAG2 mice developed more invasive tumours with an increased 
amount of distant metastases than parental mice. Recently, transgenic expression 
of a constitutively active IGF-1R fusion protein in mice resulted in spontaneous 
development of invasive adenocarcinomas of salivary and mammary glands [21]. The 
above-mentioned studies provide proof of principle that active IGF-1R signalling 
facilitates malignant transformation, drives growth and progression of established 
tumours and enhances capability to invade and metastasise. 
Figure 3. Endocrine Regulation and Function of IGF-1 and the Connections with Metabolic and 
Reproductive Functions Through Interaction with Insulin and Steroid Hormones (IGFBP, IGF binding 
protein; GHR, growth hormone receptor; SHBG, sex hormone binding globulin).
The tumour promoting functions of IGF-1R are embedded in the multi-dimensional 
process of cancer development and progression. Increased IGF-1R activation, by 
GH/IGF-1 status or other mechanisms, might create an anti-apoptotic environment 
thereby favouring cell survival and malignant transformation. Oncogenes, such as the 
Hepatitis-B Virus oncoprotein (HBx) or Ewing Sarcoma fusion proteins, recruit and 
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activate the IGF-1R signalling pathway by increasing transcription of the IGF-1R 
gene, while loss of tumour suppressor genes, such as p53, BRCA1 or WT1, results in 
IGF-1R overexpression by loss of transcriptional control [22]. Overexpression of IGF-
1R in tumour compared to normal tissue is shown in a number of studies with PCR 
detection of IGF-1R mRNA [23,24]. Amplification of the IGF-1R gene, however, is 
infrequent, as shown in breast tumours (<2%) [25,26] and sarcomas [27]. Activating 
mutations of the receptor have not been described yet. Numerous other molecular 
mechanisms that modulate IGF-1R signalling in cancer, such as loss of imprinting of 
IGF-2, altered glycosylation and constitutive activation of downstream proteins, have 
been described (for a recent review see Ref. 28). Upregulation of IGF-1R signalling 
has recently been implicated in the development of resistance to anti-cancer therapy, 
such as radiotherapy, hormonal therapy and human epidermal growth factor receptor 
2 (HER2) targeting [29,30]. Signalling through hybrid-Rs and IR-A may produce 
similar tumour promoting effects. Substantiating data from hybrid-R or IR-A knock-
out and overexpression models are currently sparse, but IR-A has e.g. been implicated 
in malignant transformation [31] autocrine loops with activation by IGF-2 [32] and 
in resistance to gefitinib in colon cancer by overexpression [33]. Concerns have been 
raised, therefore, that blocking the IGF-1R might not suffice to abolish all tumour 
promoting effects of the IGF-1R system.
Development of IGF-1R targeting strategies 
A number of approaches have been explored to therapeutically interfere in IGF-1R 
signalling, such as reducing ligand availability by GH antagonists, IGF-1- and IGF-2-
antibodies and recombinant human IGFBPs, reducing IGF-1R expression by anti-sense 
and RNA interference, or inhibiting IGF-1R activation by IGF-1R antibodies and 
small molecule tyrosine kinase inhibitors (TKIs) [34]. In vitro and in vivo inhibition 
of IGF-1R signalling in tumour cells resulted in striking apoptosis in malignant cells 
growing in anchorage independent conditions and dramatic inhibition of tumour 
formation after injection in nude mice [35,36]. 
At present, antibodies and TKIs have become readily available for clinical use. IGF-
1R antibodies are currently in phase I and II clinical trials and several IGF-1R TKIs 
have preclinically been characterised (Table 1). Binding of IGF-1R antibodies to the 
receptor prevent ligand-induced activation and induce receptor internalisation and 
degradation by endocytosis [51]. Receptor downregulation is considered to contribute 
importantly to the induction of apoptosis seen with IGF-1R antibodies [35]. Preclinical 
characterisation of IGF-1R antibodies revealed ability to bind and internalise both 
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IGF-1R and hybrid-Rs, while no binding affinity for IR was present [52,53]. For 
prevention of adverse effects on glucose and carbohydrate metabolism it is desirable 
to leave IR intact, however, with this approach mitogenic insulin and IGF-2 signalling 
through the IR-A will be unaffected. Hypothetically, it might prove a functional 
approach to block auto- and paracrine IGF-2 signalling through the IR-A using IGF-2 
antibodies in a subset of tumours that progress due to IR-A signalling. Selective human 
monoclonal IGF-2 antibodies are currently being developed and characterised [54]. 
Future studies are needed to clarify the importance of IR-A signalling in tumours. 
A recent study suggests that IGF-1R blockage might also lead to a reactive increase 
in insulin sensitivity [55]. Special attention might, therefore, be needed to prevent 
hyperinsulinaemia in patients receiving IGF-1R antibodies.
Table 1. Monoclonal Antibodies and Small Molecule Tyrosine Kinase Inhibitors (TKIs) Targeted at the 
IGF-1R in the Frontline of Early Clinical and Preclinical Development
Preliminary results from phase I trials with Pfizer’s CP-751,871 and Imclone’s A12 
show no dose limiting toxicities [56,57]. Infrequently mild transient hyperglycaemia 
developed, which in some cases was attributable to the combination with steroids. 
Hypoglycaemia, a potential result from increased insulin sensitivity, has so far not been 
reported. IGF-1R antibodies demonstrated in vitro activity to numerous solid tumours 
(breast, lung, colon, cervical, ovarian, pancreatic, melanoma, prostate, neuroblastoma, 
rhabdomyosarcoma, osteosarcoma) and multiple myeloma (MM) [37,39–43,58,59]. 
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In vivo tumour regression and growth arrest by IGF-1R antibodies was confirmed 
in subcutaneous xenografts and metastatic models of breast, colon, lung, pancreas, 
prostate, ovarian and MM tumours. Monotherapy, as well as combinations of IGF-
1R antibodies with chemotherapy, targeted therapy and radiation, such as 5-FU 
and irinotecan in colon tumour xenografts, gemcitabine for pancreatic tumours, 
melphalan for multiple myeloma, tamoxifen in breast tumours, anti-EGFR in lung 
tumours and radiation in lung tumours, were effective and induced 60–100% tumour 
regressions [37,39–41,58,60,61]. Early evidence of clinical activity in various solid 
tumours, hormone refractory prostate cancer and multiple myeloma has been reported 
[56,57,62]. Interestingly, at doses of 3 mg/kg the IGF-1R expression in peripheral 
blood mononuclear cells (PBMCs) was completely abrogated, meaning that IGF-1R 
downregulation in PBMCs could provide a functional biomarker for  adequate dose 
finding [56]. 
Table 2. IGF-1R in Clinical Samples of Primary Colorectal Tumours, Prostate Tumours, Ewing’s 
Sarcoma (ES), Osteosarcoma and Multiple Myeloma (MM): Correlations with Tumour Grade and 
Survival
TKIs inhibit receptor activation by directly binding to and blocking the catalytic 
kinase domain. As the kinase domain of IGF-1R and IR are nearly identical, it is 
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hard to achieve specificity for IGF-1R over IR and therefore the chance of undesirable 
effects of co-targeting the insulin receptor is not hypothetical [63]. Examples of TKIs 
with specificity for IGF-1R over IR are Novartis’ compounds NVP-AEW541 and 
-ADW742 [47,48]. Bristol–Myer Squibb, on the other hand, has developed TKIs 
targeting both IGF-1R and IR, BMS-55417 and -536924 [21,46]. No data currently 
exist on the effects of IGF-1R TKIs on hybrid-R signalling. Interestingly, IGF-1R 
specific inhibitors, PPP and NVP- AEW541, decreased blood glucose levels in mice, 
due to increased glucose uptake in IGF-1R positive, but not in IGF-1R negative, cells 
[45,64]. BMS compounds, on the other hand, induced diabetogenic effects in vivo 
[46] but addition of metformin reduced hyperglycaemia [63]. The choice of metformin 
is rational, since metformin reduces hepatic gluconeogenesis and intestinal glucose 
absorption, while stimulating insulin sensitivity without increasing insulin levels.
Table 3. IGF-1R, Insulin Receptor (IR) and Hybrid-R in Clinical Primary Breast Cancer Samples: 
Correlations with Pathological Parameters and Survival
In vitro activity of TKIs has been shown in a panel of solid tumours (ovarian, prostate, 
breast, lung, colon, thyroid, ovarian, renal, adrenal and neuroendocrine tumours, 
mesothelioma, hepatocellular carcinoma, melanoma, sarcomas and retinoblastoma) 
and haematological tumours (MM, various subtypes of leukemias and lymphomas). 
In vivo activity of TKIs was demonstrated in animal models of Ewing’s Sarcoma, uveal 
melanoma, prostate cancer, neuroblastoma, fibrosarcoma and MM [46–48,64–68]. 
Synergistic effects were seen when IGF-1R TKIs were combined with vincristine in 
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Ewing’s Sarcoma and melphalan in MM [47,68]. One broad spectrum TKI with 
reported activity against the IGF-1R (Insm-18) is currently in phase I clinical trial. This 
compound inhibits activity of e.g. platelet-derived growth factor receptor (PDGFR) 
and HER2, as well [49]. Notably, decreased VEGF production and disturbed 
angiogenesis has been demonstrated in various models following IGF-1R inhibition 
[61,64]. Disruption of IGF-1R may be effective against tumour neovascularisation. 
Potential of IGF-1R targeting in various tumour types 
IGF-1R is frequently overexpressed in a wide range of tumour types (Table 2). Although 
correlations with clinical or pathological parameters are infrequently found, IGF-1R may 
represent a common target in a spectrum of tumour types, considering the wide range 
of tumours that are sensitive to IGF-1R blockade by antibodies and TKIs in vitro and 
in vivo. Among tumour types and cell lines of same tumour types, however, differential 
sensitivity to IGF-1R drugs is seen [40,46,47]. No activity of the IGF-1R inhibitor 
PPP has been shown in IGF-1R negative cells [45] and weaker effects of antibody A12 
in a low IGF-1R expressing MM model compared to a high expressing IGF-1R MM 
model [61] However, the degree of sensitivity cannot completely be related to IGF-1R 
expression and, interestingly, MM as a group were more sensitive to the anti-neoplastic 
effects of NVP-ADW472 than any other tumour group [47]. The correlation of IGF-
1R expression with clinical and biological parameters is currently most well defined in 
breast cancer (Table 3). Highly variable percentages (39–93%) of breast carcinomas 
expressing high levels of IGF-1R are reported, most likely because a uniform method to 
assess the IGF-1R expression level is lacking. Although controversy still exists [85,86], 
IGF-1R expression in breast cancer is correlated with hormone receptor expression and 
well-differentiated tumours in most studies [84,88,94]. A correlation with prognosis 
is not consistently demonstrated. Interestingly, Railo et al. [90] found worse survival 
rates in ER negative IGF-1R expressing tumours, while Ueda et al. [84] recently 
described a favourable prognosis for IGF-1R expression in ER positive tumours. This 
observation of a differential effect of IGF-1R expression on prognosis in ER positive 
versus ER negative tumours is supported by in vitro studies. In breast cancer cell lines 
IGF-1R and ER synergistically stimulate proliferation [98], but in the absence of ER, 
IGF-1R activation fails to induce mitogenesis, while its migratory actions are retained 
[99,100]. It could be hypothesised that well differentiated, ER positive breast cancers 
retain physiological growth control by ER and IGF-1R signalling, while in ER negative 
tumours IGF-1R expression confers primarily metastatic capacities.
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In prostate cancer, a same close conjunction is seen between IGF-1R and androgen 
receptor [101]. Interestingly, differential effects of IGF-1R targeting have been 
demonstrated in androgen dependent versus hormone refractory prostate cancer 
models in vivo [59]. While IGF-1R antibody A12 caused apoptosis and abrogated 
G1-S phase transition in androgen dependent prostate tumours, IGF-1R inhibition 
led to G2M arrest in hormone refractory tumours. Because IGF-1R and hormone 
receptors closely interact, a combination of hormonal therapy with IGF-1R drugs may 
be necessary to block all mitogenic hormonal responses and may prevent development 
of hormone resistance, as modulations of the IGF-1R system have been implicated 
in development of resistance to endocrine therapies in breast and prostate cancer 
[30,101]. In breast cancer cell lines, the IGF-1R has also been shown to interact with 
and activate the HER2 receptor in cells resistant to anti-HER2 therapy (trastuzumab) 
and this interaction could be disturbed by lapatinib (a dual EGFR/HER2 TKI) as well 
as IGF-1R antibodies [102]. This suggests that patients with disease progression on 
trastuzumab therapy might benefit from IGF-1R antibodies. 
In Ewing’s Sarcoma IGF-1R expression is a result of the actions of the EWS-ETS 
fusion proteins, which are fundamental to development of Ewing’s Sarcoma. In clinical 
samples, De Alava et al. demonstrated a relation between a functionally weaker and 
clinically favourable member of the EWS-ETS family of fusion proteins, EWS-FL1 
type 1, a lower proliferative rate and lower levels of IGF-1R expression [79]. As the 
EWS-ETS fusion proteins are transcription factors, whose function cannot easily be 
blocked, it is promising that it may soon become possible and prove effective to block 
its targets, among which the IGF-1R. Blocking the IGF-1R has demonstrated in vivo 
effects in Ewing’s sarcoma by several approaches [64,68,103,104].
Concluding remarks
Although responses to IGF-1R drugs are anticipated in a wide range of tumours based 
on in vitro and in vivo results, the clinical and biological correlates of IGF-1R response 
in tumours are poorly understood. Considering previous experiences with RTK 
targeting drugs, the concept that IGF-1R drugs will be widely applicable in anticancer 
therapy due to ubiquitous expression of IGF-1R in tumours might prove not to be 
true. Biomarkers are urgently needed to predict responses and select patients who may 
benefit from IGF-1R targeted therapy. Further dissection of the mechanistic basis of 
IGF-1R and IR function could improve specificity and efficiency of IGF-1R targeting 
within the context of a highly versatile receptor system. Such knowledge should translate 
into strategies which block tumour promoting elements of the IGF-1R/IR-system and 
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avoid hitting vital metabolic functions. In this respect, the role of signalling via IR-A 
signalling and downstream proteins, such as IRS-1 and -2, is emerging. Also, joint 
efforts of oncologists and endocrinologists might manage issues related to diabetogenic 
side effects and compensatory mechanisms resulting from IGF-1R targeted therapy, 
such as increased insulin sensitivity and increases in glucose uptake. With upcoming 
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versus triple negative invasive ductal 
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Abstract
The type 1 insulin-like growth factor receptor (IGF-1R) is involved in progression of 
breast cancer and resistance to systemic treatment. Targeting IGF-1R signaling may, 
therefore, be beneficial in systemic treatment. We report the effect of IGF-1R expression 
on prognosis in invasive ductal breast carcinoma (IDC), the most common type of 
breast cancer. Immunohistochemistry was performed on tumor tissue of a consecutive 
cohort of 429 female patients treated for operable primary IDC. Associations between 
IGF-1R expression with clinicopathological parameters, disease free survival (DFS) 
and breast cancer specific survival (BCSS) were evaluated by multivariate analyses 
focusing on ER-positive and triple negative IDC (TN-IDC). To enlarge the TN-IDCs 
cohort, we analyzed a combined dataset of 51 TN-IDC tumors from our series with 64 
TN-IDCs with similar clinicopathological parameters. Patients with tumors expressing 
cytoplasmic IGF-1R have a longer DFS and BCSS (DFS: HR 0.46, 95% CI 0.27–
0.49, P = 0.005, BCSS: HR 0.38, 95% CI 0.19–0.74, P = 0.005). This effect was most 
prominent in ER-positive tumors. However, in a combined series of 105 TN-IDCs 
cytoplasmic IGF-1R expression was associated with a shorter DFS (HR = 2.29, 95% 
CI 1.08–4.84, P = 0.03), also when combined in a multivariate model, including well-
known prognostic factors (HR 2.06; 95% CI 0.95–4.47; P = 0.07). IGF-1R expression 
in ER-positive IDC is strongly related to a favorable DFS and BCSS, but to a shorter 
DFS in TN-IDC tumors. This divergent effect of IGF-1R expression in subgroups of 
IDC may affect selection of patients for IGF-1R targeted therapy
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Introduction
Signaling via the type 1 insulin-like growth factor receptor (IGF-1R) plays a crucial 
role in proliferation, cell survival, invasion, and metastatic behavior of many cancers, 
including breast cancer [1, 2]. In addition, IGF-1R is implicated in resistance to 
chemotherapy, hormonal therapy, Human Epidermal Growth Factor Receptor 2 
(HER2) and Epidermal Growth Factor Receptor (EGFR) directed therapies [3–5]. 
IGF-1R is a transmembrane tyrosine kinase receptor activated by binding of IGF-
1 or -2 [6]. Subsequently, signaling occurs via Src homology 2 domain-containing 
protein, insulin receptor substrates, phosphatidylinositol-3-kinase/Akt, and mitogen-
activated protein kinase pathways [7–9]. High IGF-1R expression levels have been 
reported in a wide range of human malignancies, but correlations with tumor 
characteristics and outcome are infrequently found [10]. Based on in vitro and in vivo 
data with IGF-1R antibodies and tyrosine kinase inhibitors, responses are expected 
in a variety of carcinomas [3, 11–14]. IGF-1R targeted therapy in breast cancer is 
particularly interesting, because synergy with anti-hormonal therapy and targeting of 
related receptor tyrosine kinases HER2 and EGFR has been shown [15–17]. There is 
evidence coming from cell line studies suggesting IGF-1R signaling has different effects 
on cellular characteristics like proliferation and migration in ER-negative tumors as 
opposed to ER-positive tumors [18–20]. However, it is still unclear which factors 
contribute to sensitivity to anti-IGF-1R directed therapy, as no biomarker is available 
yet to select patients and tumor types. 
Breast cancer is a heterogeneous disease with different sensitivity to drug treatment 
and outcome between different histological and molecular subtypes [21, 22]. Previous 
studies showed high IGF-1R expression in human breast carcinomas [23–27] and 
several studies showed correlations of IGF-1R expression with estrogen receptor 
expression and well-differentiated carcinomas [23, 27, 28]. A special subgroup of breast 
carcinomas, called triple negatives (TNs), defined by absence of estrogen receptor (ER), 
progesterone receptor (PR), and HER2 expression, has a worse prognosis and lacks a 
scaffold for conventional targeted treatments [29]. Identification of new targets in TNs 
is warranted to extend the armamentarium for this relatively poor prognostic subgroup 
of breast cancer. The IGF-1R could be a target and thereby providing new treatment 
options. In the current study, IGF-1R expression was investigated in a consecutive 
cohort of patients with invasive ductal carcinomas (IDCs) of the breast. 
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In this way, the value of IGF-1R expression in the most prevalent histological subtype 
can be related to patient and tumor characteristics, molecular markers, and prognosis. 
For above-mentioned reasons special attention will be put on TN-IDCs. For the latter, 
we combined two datasets of TN-IDCs with similar clinicopathological parameters. 
Patients, materials, and methods
A consecutive cohort of 429 female patients treated for a primary local or locally 
advanced invasive ductal breast carcinoma, as defined by the WHO classification [30] 
at the University Medical Center Groningen between January 1996 and December 
2005 was included in this study. In this same period 26 patients presented with a 
synchronous (n = 4) or metachronous (n = 18) contralateral breast tumor or a recidive 
tumor (n = 4), these patients were not included in our cohort. 
All patients received local treatment, i.e., breast conserving therapy including 
radiotherapy or ablative surgery, both with lymph node staging (sentinel node 
procedure and/or axillary dissection). Local therapy was followed by chemotherapy 
in 118 patients (96/118 anthracycline-containing chemotherapy (AC/FEC/CAF); 
20/118 cyclophosphamide, methotrexate, and fluorouracil (CMF); 2/118 taxane 
based). In 55 patients chemotherapy was combined with endocrine treatment, 97 
other patients received only endocrine systemic treatment (total n = 152; 121/146 
tamoxifen; 24/146 aromatase inhibitor; in 7 patients who remained premenopausal 
after received chemotherapy, a LHRH analogue was added). Only 4 patients received 
herceptin. Patient and tumor characteristics and data on follow-up were obtained from 
hospital records (Table 1). The medical ethical committee of the University Medical 
Center Groningen approved this study. 
To study a subgroup of patients in more detail, 51 triple negative breast carcinomas 
(TN-IDCs) from the cohort described above (Groningen dataset) were combined with 
a previously described cohort of 71 TN tumors (Amsterdam dataset) [31], from which 
64 were invasive ductal carcinomas and evaluable for IGF-1R expression in our study. 
The two populations were similar with regard to patient and tumor characteristics, 
local and systemic therapy and survival (Supplementary Table 1). 
A tissue microarray was constructed as previously described [32, 33]. TMA sections 
were stained with antibodies against IGF-1R, insulin receptor (IR), phosphorylated-Akt 
(p-Akt), ER, PR, and HER2. Specific details of the antibodies and their antigen retrieval 
methods used are summarized in Supplementary Table 2. The immunohistochemical 
methods in general were previously described by van der Vegt et al. [34] for ER, PR, 
and HER2 staining. 
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Scoring of the immunohistochemical staining was performed by a consultant breast 
pathologist (JW). ER and PR were assessed based on the percentage of tumor cells 
showing positive nuclear staining and were considered positive if nuclear staining was 
present in ≥10% of the cells, according to Dutch guidelines (www.oncoline.nl). HER2 
expression was scored as follows: 0 for no staining at all or membrane staining in <10% 
of the tumor cells; 1+ for a faint/barely perceptible partial membrane staining in >10% 
of the tumor cells; 2+ for weak to moderate complete membrane staining in >10% 
of the tumor cells; 3+ for strong complete membrane staining in >10%. HER2 was 
considered positive if the score was 3+. IR and p-Akt were considered positive if either 
membranous or cytoplasmic staining was present in ≥10% of the cells. 
IGF-1R expression, analogue to HER2 expression, was considered positive with strong 
complete staining pattern in >10% of tumor cells as depicted in Fig. 1. To confirm 
the robustness of the staining pattern for IGF-1R using the 24–31 antibody, a tissue 
microarray of 50 consecutive invasive breast carcinomas was stained using the same 
clone provided by another supplier (clone 24–31, Neomarkers, Fremont CA, USA; 
dilution 1/800). Each individual core of both stained tissue microarrays can be seen at 
http://telepathology.nki.nl (Login: IGF-1R, Password: nki-avl). For all stainings, the 
highest score out of three cores from the same tumor was used for the analysis. If one 
or two cores out of three failed, the highest value of the remaining core(s) was included 
in the analysis. Only the invasive tumor component was considered when judging the 
staining. When no (invasive) tumor cells were available in the sample, the result was 
considered ‘missing’ in the statistical analysis.
Since the clinical relevance of IGF-1R localization is yet unknown, separate analyses 
were conducted for (1) positive cytoplasmic IGF-1R staining vs. no cytoplasmic 
staining, (2) positive membranous vs. no membranous staining and (3) any positive 
staining (cytoplasmic, membranous, or both) vs. negative staining pattern (further 
addressed as “overall IGF-1R expression”). 
Univariate and multiple logistic regression analyses were performed to evaluate the 
associations of IGF-1R expression with clinical (age, menopausal status, lymph node 
status, surgical, and adjuvant therapy), tumor (size and differentiation grade), and 
immunohistochemical (ER, PR, IR, HER2, and p-Akt) characteristics. Multivariate 
Cox regression analysis was used to explore the relationship between IGF-1R and the 
following survival endpoints; (1) disease free survival (DFS), defined as time to any 
recurrence (local or regional or distant), and (2) breast cancer specific survival (BCSS). 
Clinicopathological variables that had a significant univariate association (Tables 2, 3) 
were entered simultaneously in a multivariate Cox regression model. Log-rank tests 
were performed to evaluate the difference in group-specific survival which is illustrated 
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by Kaplan–Univariate and multiple logistic regression analyses were performed to 
evaluate the associations of IGF-1R expression with clinical (age, menopausal status, 
lymph node status, surgical, and adjuvant therapy), tumor (size and differentiation 
grade), and immunohistochemical (ER, PR, IR, HER2, and p-Akt) characteristics. 
Table 1. Patient and Tumor Characteristics
IDC invasive ductal carcinoma no special type, DCIS ductal carcinoma in situ, 
BCT breast conserving therapy
41
Multivariate Cox regression analysis was used to explore the relationship between IGF-
1R and the following survival endpoints; (1) disease free survival (DFS), defined as time 
to any recurrence (local or regional or distant), and (2) breast cancer specific survival 
(BCSS). Clinicopathological variables that had a significant univariate association 
(Tables 2, 3) were entered simultaneously in a multivariate Cox regression model. Log-
rank tests were performed to evaluate the difference in group-specific survival which 
is illustrated by Kaplan–Meier plots. All statistical analyses were performed using the 
statistical package SPSS 16.0 (SPSS inc., Chicago, IL, USA). 
Results
Immunohistochemistry
Immunohistochemistry for IGF-1R could be evaluated in 368 cases (86%). In case 
IGF-1R was present, the intensity of the staining was strong and uniformly present in 
all tumor cells in 295 cases (80%). Pure membranous IGF-1R expression was present 
in 8%, pure cytoplasmic in 21%, and both membranous and cytoplasmic staining in 
51%. An overview of other assessed immunohistochemical markers is summarized in 
Supplementary Table 3. 
Association of IGF-1R staining pattern with clinicopathological parameters
The univariate association of IGF-1R cytoplasmic and membranous expression with 
patient and tumor characteristics is summarized in Supplementary Table 4. In a 
multiple logistic regression model, including tumor size, differentiation grade of the 
tumor, ER and PR expression, ER was strongly associated with IGF-1R cytoplasmic 
expression (OR = 4.18; 95% CI 2.07–8.44, P < 0.001) and IGF-1R overall staining 
(OR = 3.22; 95% CI 1.54–6.74, P = 0.002). No relation with p-Akt or IR expression 
was found. 
Prognostic relevance of IGF-1R staining pattern
Cytoplasmic, but not membranous or overall IGF-1R expression was strongly associated 
with prolonged DFS (HR 0.46, 95% CI 0.27–0.49, P = 0.005) and increased BCSS 
(HR 0.38, 95% CI 0.19–0.74, P = 0.005) (Figure 2). Tumor size, differentiation grade, 
and PR were multivariately significant factors for DFS (Table 4). 
Interestingly, while in ER-positive tumors cytoplasmic IGF-1R expression is a favorable 
prognostic factor, in ER-negative tumors this effect is lost and membranous staining is 
related to a worse prognosis (DFS) (log-rank P = 0.02) (Fig. 3). 
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Figure 1. A–F Location Patterns of IGF-1R Immunohistochemical Staining: A&B Cytoplasmic 
(Magnification ×10, ×20); C&D Membranous (×10, ×20), and E&F Membranous and Cytoplasmic 
(×10, ×20)
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Subsequently, significant univariate parameters for BCSS (Table 3) were analyzed by 
multivariate Cox regression in which differentiation grade and HER2 were prognostic 
factors (Supplementary Table 5). 
Effect of IGF-1R expression in triple negative breast carcinomas
This interesting result, i.e., a possible opposite effect of IGF-1R expression on prognosis 
of ER-positive versus ER-negative tumors, led us to investigate the effect of IGF-1R 
expression in a cohort of TN-IDCs. Because there were only 51 such cases in our 
cohort (University Medical Center Groningen; referred to as Groningen dataset), we 
combined these with a previously described cohort of 64 evaluable cases of TN-IDCs 
from another center (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital; 
referred to as Amsterdam dataset) [31] with similar patient and tumor characteristics 
and survival (Supplementary Table 1). For the Amsterdam cohort, the majority of 
patients was treated by breast conserving therapy (BCT) including post-operative 
radiotherapy, whereas for the Groningen dataset approximately halve of the patients 
were treated by BCT. Immunohistochemistry for IGF-1R could be evaluated in 105 
triple negative cases (91%). IGF-1R was expressed in 52 cases (45%). Pure cytoplasmic 
IGF-1R expression was present in 11 cases (10%) and pure membranous IGF-1R 
expression in 11 cases (10%). In total, 30 cases (26%) had combined membranous and 
cytoplasmic staining. We found no association between membranous or cytoplasmic 
IGF-1R expression and clinicopathological parameters. In the combined patient cohort 
of 105 TN-IDCs, cytoplasmic IGF-1R expression has an unfavorable prognostic 
impact on DFS (cytoplasmic: HR = 2.29, 95% CI 1.08–4.84, P = 0.03; membranous: 
HR 1.98; 95% CI 0.94–4.17, P = 0.07). Comparable direction and magnitude of 
effects were seen in both triple negative databases separately (cytoplasmic HR 2.99 
and 1.83 resp.; membranous HR 1.58 and 1.83 resp.), although not consistently 
statistically significant, most likely due to lower numbers in the separate databases, and 
thus reduced power. In a multivariate analysis, including all well-known prognostic 
clinicopathological parameters, cytoplasmic IGF-1R expression was a near-significant 
prognostic factor for DFS (HR 2.06; 95% CI 0.95–4.47; P = 0.07) (Table 5). These 
same associations were also found when only time to distant metastasis was tested 
(cytoplasmic: HR 2.69, 95% CI 1.16–6.22, P = 0.02; membranous: HR 2.74, 95% 
CI 1.18–6.32, P = 0.02). Both cytoplasmic (HR 2.43, 95% CI 1.02–5.8, P = 0.04) 
and membranous staining (HR 2.64, 95% CI 1.11–6.31, P = 0.03) were multivariately 
related to time to distant metastases. No association between IGF-1R expression and 
BCSS could be demonstrated in triple negative cases.
44
Table 2. Univariate Cox Regression Analysis of Clinicopathological Parameters and Disease Free Survival 
(DFS)
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Figure 2. Kaplan–Meier Plots of Associations of IGF-1R Expression with Disease Free Survival (A) and 
Breast Cancer Specific Survival (B) in Months
Discussion
In this study, we found that cytoplasmic expression of IGF-1R in ER-positive invasive 
ductal breast carcinomas is associated to a more favorable prognosis while in triple 
negative breast carcinomas IGF-1R expression is associated to a poor outcome. This 
study underlines that the clinical impact of transmembrane tyrosine kinase receptor 
expression should be interpreted in the context of the carcinoma subtype, such as co-
expression with hormone receptors. We found IGF-1R expression in 80% in our series 
of invasive ductal breast carcinomas (IDC). The majority of these tumors (62%) had 
combined cytoplasmic and membranous staining. Since the clinical relevance of IGF-
1R localization is yet unknown and our goal of the present study was evaluation of a 
candidate prognostic biomarker that would be clinical applicable, separate analyses 
were conducted for cytoplasmic, membranous, and overall staining. 
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Table 3. Multivariate Cox Regression on Disease Free Survival (Number of Events = 61; Number of 
Patients = 341)
Cytoplasmic IGF-1R staining highly correlated with hormone receptor expression, well 
differentiated breast carcinomas, and to a more favorable prognosis. This prognostic 
effect occurred specifically in ER-positive breast carcinomas. Since cytoplasmic staining 
patterns of tumor samples incorporated on the same TMA-slide show differential 
staining intensity and subsequent significant correlation with biologic plausible factors, 
we considered this not an artifact but a relevant observation that should not a priori be 
ignored. Moreover, the robustness of IGF-1R staining intensity and staining pattern 
was confirmed using an antibody of the same clone provided by another supplier 
on a tissue microarray of 50 randomly chosen invasive breast carcinomas. Although 
the biologic significance of cytoplasmic localization of the IGF-1R has received little 
attention in the literature up till now, cytoplasmic localization has been observed 
before. Confocal microscopy images studying subcellular localization of IGF-1R show 
cytoplasmic staining [35, 36]. Some have reported cytoplasmic IGF-1R staining by 
IHC [37, 38], while others have chosen to ignore cytoplasmic staining, although 
endoplasmatic staining has been present [39].
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IHC [37, 38], while others have chosen to ignore cytoplasmic staining, although 
endoplasmatic staining had been present [39].
Figure 3. Kaplan–Meier Plots of Group-Specific Associations of IGF-1R Expression with Disease Free 
Survival in ER-Positive (A) and ER-Negative (B) Breast Carcinomas
Biologically cytoplasmic IGF-1R has been linked to mutant receptors which show 
abolished cell surface expression and endoplasmatic retention of the receptor due to 
failure to traffic to the cell membrane [40]. Also, accumulation of IGF-1R into the 
cytoplasm has been observed after internalization and intracellular trafficking induced 
by binding of ligand or antibodies, resulting in receptor degradation [36]. Most of the 
biologic effects of the IGF-1R have been ascribed to its tyrosine kinase activity, which 
propagates signaling through the phosphatidylinositol 3-kinase and mitogen-activated 
protein kinase pathways. Recently, however, IGF-1R translocation to the nucleus has 
been described and shown to activate transcription but not alter its kinase-dependent 
signaling [41, 42]. 
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Table 4. Univariate Cox Regression Analysis of Patient, Tumor and Treatment Characteristics with 
Breast Cancer Specific Survival (BCSS)
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Table 5. Multivariate Cox Regression on Disease Free Survival in Triple Negative Invasive Ductal Breast 
Carcinomas (Number of Events = 28, Number of Patients = 101)
This is analogue to the earlier observation that ErbB family proteins are expressed in 
the nucleus and can function as transcriptional regulators [43]. Although cytoplasmic 
or nuclear HER2 staining by IHC in clinical tumor samples is not considered to be 
relevant for prognosis or selection of HER2 targeted therapy, the biological relevance 
of nucleo-cytoplasmic trafficking has been accepted.  In our samples, nuclear IGF-1R 
expression did not become evident. Of particular interest is the relation of IGF-1R 
localization with ER expression. Interaction of IGF-1R and ER has been shown in 
numerous studies, but this interaction also involves physical co-localization. Reported 
co-localization of the ER, which is generally localized in the nucleus, with IGF-1R at 
the cell membrane underscores the diversity of receptor localization [35]. 
Taken together, these data suggest that protein localization of tyrosine kinase receptors 
is a highly dynamic biological process. The specific details of functional implications of 
IGF-1R cytoplasmic localization need to be appreciated in future studies. 
In previous studies, similar associations of ER and IGF-1R expression were reported 
[27, 28, 44], e.g., Ueda et al. [27] described a favorable prognosis for IGF-1R expression 
in ER-positive carcinomas. In triple negative breast carcinomas (TN-IDCs) we found 
IGF-1R expression in 65% of the cases. In these tumors cytoplasmic staining showed 
some relation to shorter DFS, although no effect was found on overall survival rates. 
In line with our results, Railo et al. [45] reported similar worse survival rates in ER-
negative IGF-1R expressing breast carcinomas. 
Our observation of a different association between IGF-1R expression and prognosis 
in ER-positive versus ER-negative carcinomas is supported by in vitro studies. In breast 
cancer cell lines IGF-1R and ER synergistically stimulate proliferation [20], but in 
the absence of ER, IGF-1R activation fails to induce mitogenesis, while its migratory 
actions are retained [18, 19]. 
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High circulating IGF-1 levels are by now a well-established risk factor in women 
for developing breast cancer [46, 47], and a most recent collaborative analysis of 17 
prospective studies established that the risk-association is confined to ER-positive 
tumors [48]. These data strongly support a notion of altered biologic and prognostic 
significance of IGF-1 and IGF-1R in ER-positive vs. ER-negative tumors as presented 
in our study. 
Most likely, IGF-1R expressing, ER-positive carcinomas represent a large subclass of 
breast carcinomas with presumably a distinct biology and an excellent prognosis. It could 
be hypothesized that well-differentiated, ER-positive breast cancers retain physiological 
growth control by ER and IGF-1R signaling, while in ER-negative carcinomas IGF-1R 
expression confers primarily metastatic capacities. 
Hormone receptor positive invasive ductal breast cancers are nowadays treated with 
adjuvant tamoxifen and/or aromatase inhibitors during 5 years or longer. Long-term 
survival benefit of hormonal therapy is reported to be 4–12% [21]. Because IGF-1R
and hormone receptors closely interact, a combination of hormonal therapy with IGF-
1R drugs may help to block all mitogenic hormonal responses. Also, as modulations 
of the IGF-1R system have been implicated in development of resistance to endocrine 
therapies, IGF-1R directed therapy may overcome or prevent development of hormone 
therapy resistance [4, 49, 50]. Indeed, synergistic effects of IGF-1R targeting drugs with 
hormonal therapies have been reported in vivo [3]. Therefore, we suppose that IGF-
1R directed therapy may complement therapy for hormone receptor positive breast 
cancers, in particular in case of constitutive or acquired resistance to endocrine therapy.
Our patient cohort covers a considerable time span, in which the indications and 
therapeutic options for surgical and systemic treatment have further been developed 
and adjusted. Surgical treatment (mastectomy vs. lumpectomy followed by radiation), 
received chemotherapy, and hormonal therapy were included in our multivariate 
survivalmodels and group by group analysis was conducted for anthracycline-
containing chemotherapy versus no chemotherapy and for tamoxifen versus no 
hormonal treatment (data not shown). Herein we found no evidence that the 
survival benefit of IGF-1R expression on prognosis in our study was compounded 
by interaction with adjuvant systemic therapy. However, changing chemotherapy 
regimens, different hormonal treatment and shifting indications for adjuvant 
treatment over this period of time could not entirely be accounted for in our models.
In the Amsterdam dataset of TN-IDC more patients were treated with breast conserving 
surgery followed by radiation than in our cohort. Breast conserving surgical therapy 
bears a slightly increased risk on local recurrence of the tumor. However, our finding 
of an unfavorable prognostic impact of IGF-1R on DFS in this population held true 
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when time to distant metastasis was tested and was not attributed to local recurrences.
The present database was considered less appropriate for studying effects on prognosis 
in HER2 positive tumors, because herceptin had not yet been introduced as a standard 
adjuvant systemic treatment in this patient group during the inclusion period of 
this study. Also, correlations with HER2 may be inaccurate, since only 3+ HER2 
cases were considered positive, and 2+ cases were not subjected to FISH analysis.
Activation of PI3K signaling, which among multiple other signals is induced by IGF-
1R, occurs often in breast carcinomas [51] and has been related to limited sensitivity to 
HER2 directed therapy [52]. We, however, found no correlation of IGF-1R expression 
with staining of phosphorylated-Akt or PTEN, neither with RNA expression of PI3K 
pathway related genes (data not shown). Therefore, we could not show PI3K to be a 
dominant pathway emerging from high IGF-1R expression and we can only speculate on 
the functional significance of positive IGF-1R expression. Since an IGF-1 signature has 
been published predicting worse prognosis of ER-positive breast carcinomas [53] it is of
interest to test whether the presence of such a signature 
is related to IGF-1R expression on the protein level.
As the IGF-1R is highly homologous to the IR, and they share several functions 
[1], IR expression was studied but no relation with clinicopathological parameters 
or IGF-1R expression pattern could be shown. Although there are data suggesting 
IR is also a favorable prognostic factor [54, 55] we could not reproduce these 
results. Among other explanations, using antibodies with different specificity 
for (splice variants) of IR and IGF-1R-IR hybrids may have played a role.
Interestingly, Law et al. [56] reported that phosphorylated IGF-1R and insulin receptor 
(IR) can be found in all breast carcinoma subtypes and is related to a poor survival. 
Whether detection of phosphorylated IGF-1R and IR outperforms the detection of 
IGF- 1R expression as presented here as a biomarker is subject of ongoing studies.
In TN-IDCs, inhibition of the IGF-1R-mediated signaling is likely to have a clear 
beneficial effect as has been shown for a mouse model carrying basal type breast 
carcinomas [57]. Within this perspective, clinical phase trials of IGF-1R antibodies 
and tyrosine kinase inhibitors or antibodies blocking the IGF-1R signaling should 
focus both on ER-positive as well as TN-IDCs. With regard to the importance of 
cytoplasmic IGF-1R expression, treatment with tyrosine kinase inhibitors may be 
advantageous over antibodies. The clinical development of antibodies against the IGF-
1R membrane receptor, however, is far ahead of the tyrosine kinase inhibitors, which 
is also understandable with regard to the expected side effects of such a treatment.
In conclusion, IGF-1R expression in invasive ductal breast carcinomas is a strong 
favorable prognostic factor in ER-positive, but highly likely an unfavorable factor in 
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TN- IDCs. The findings of our study combined with those of others strongly suggest 
that targeting IGF-1R signaling is likely to be a promising treatment strategy of IGF-
1R expressing breast carcinomas. Clearly, further validation studies according to well-
established criteria are required to implement the IGF-1R as a biomarker 
that could assist making a rational choice for IGF-1R targeted therapy [58].
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separation of whole blood samples
Abstract
Epidemiological studies benefit from unbiased blood specimens collected with minimal 
cost and effort of blood collection and storage. We evaluated the stability of IGF-1 and 
IGFBP-3 in whole blood samples stored at room temperature to justify delays in blood 
processing. Total IGF-1 and IGFBP-3 levels were measured in EDTA plasma (n = 
12), heparin plasma (n = 12) and serum (n = 10) samples of healthy volunteers after 
blood processing delays up till 14 days. Stability of measured IGF-1 and IGFBP-3 
levels was tested by paired t-test and a linear mixed effect model. Longitudinal analysis 
showed that IGF-1 levels were not significantly affected by blood processing delays 
in EDTA tubes (p = 0.18) and IGFBP-3 levels were marginally stable (p = 0.06). In 
heparin plasma and serum, however, IGF-1 increased over time of delayed processing 
and IGFBP-3 levels tended to decrease (p < 0.01). Total IGF-1 and IGFBP-3 levels 
are stable in whole blood collected in EDTA tubes at room temperature up till 7 days, 
allowing a delay in blood processing to reduce costs in large multi-center studies.
63
Introduction
Cost and complexity of blood sample collection in large population-based or multi-
centre studies could be reduced when sample storage and processing are performed 
under less stringent conditions. However, simplification of these procedures should 
not compromise validity and reproducibility of test results. Therefore, information 
about the stability of compounds of interest should be obtained before deviating from 
standard guidelines.
Two compounds of interest in clinical epidemiological studies are the Insulin-like 
Growth Factor (IGF)-1 and IGF-Binding Protein (IGFBP)-3. An important role for 
IGF-1 in tumour development and progression has been established and several large 
multi-center cohort studies are in progress to uncover the correlates of this relation [1, 
2].
IGF-1 is a 70 amino acid single chain polypeptide with a high structural similarity with 
insulin. The production of IGF-1 in the liver is stimulated by growth hormone (GH) and 
IGF-1 mediates the endocrine actions of GH to stimulate body-wide cell proliferation 
and differentiation [3]. IGF-1 serum levels are mainly dependent on growth hormone 
stimulation and levels decrease with age after peaking in puberty. They are further 
associated with length and nutritional status [4]. In the absence of an intracellular 
storage capacity, the total amount of IGF-1 in serum functions as a reservoir by the 
formation of large molecular weight complexes with IGF binding proteins (IGFBP-1 
to -6) and acid-labile subunit (ALS). IGFBP-3 is the main binding partner of IGF-1 in 
blood. Less than 1% remains unbound (free IGF-1) and is considered a determinant 
of biological activity [3].
In the present study, we tested the stability of IGF-1 and IGFBP-3 in whole blood 
to explore the feasibility of handling of blood samples in large population-based 
epidemiological studies.
Methods
Blood samples from healthy non-fasting female volunteers, aged 24 to 57 years, were 
collected during one venapuncture into seven 4-mL serum tubes with gel (n = 10), 
seven 3-mL tubes with 7.5% EDTA (ethylene diamine tetra-acetic acid) (n = 12) or 
seven 4-mL heparin tubes with 60 IU lithium heparin (n = 12) (Vacutainer®, Becton 
Dickinson Vacutainer Systems, Plymouth, UK). Three of in total 70 serum samples 
were lost for analysis due to sampling failure. 
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 Figure 1. Individual Time-Effect Curves Showing Effects of Blood Processing Delay on Total IGF-1 
Levels in EDTA Plasma (A), Heparin Plasma (B) and Serum Samples (C), and on IGFBP-3 Levels in 
EDTA Plasma (D), Heparin (E) and Serum (F).
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Samples were kept in an airconditioned laboratory at a temperature of approximately 
20 °C, unopened and sheltered from direct sunlight until blood processing. To mimic 
various periods of delay and test even extreme delays, blood samples were processed 
after 2, 8, 24, 72, 168 h (7 days) and 336 h (14 days). One sample was processed 
within 15 min after blood collection and served as reference value. Blood samples 
were centrifuged for 5 min at 1500 ×g and serum or plasma was stored in two 0.5 mL 
aliquots at − 80 °C until time of analysis. 
Total IGF-1 and IGFBP-3 were measured by automated chemiluminescence assay 
using Immulite system and reagents (Siemens Diagnostics, Los Angeles CA, USA). 
Intra- and interassay variability were estimated at two concentrations in at least 10 runs 
and two repetitions per run. Intra- and interassay variability of IGF-1 measurements 
were 1.7% and 2.1%, respectively, measured at 8.76 nmol/L, and 1.7% and 1.2% at 
28.83 nmol/L. Intra- and interassay variability of IGFBP-3 measurements were 2.0% 
and 2.7%, respectively, measured at 0.94 µg/mL, and 2.7% and 1.0%, at 3.99 µg/mL.
Time series of all variables were plotted. Effects of delayed blood processing are 
described as individual changes from the reference value (means ± SD) at delayed 
blood processing times and were tested by paired t-test. To estimate the change in IGF-
1 (nmol/L) and IGFBP-3 (µg/mL) plasma and serum levels we performed linear mixed 
effect models with time in hours as a linear independent variable [5].
SPSS version 14.0 was used to perform the descriptive statistics and test differences 
between groups. LME analyses were performed in S-plus 2000 (Insightful Corporation, 
Seattle, WA, USA). p-values of < 0.05 were considered to be statistically significant.
Results
Visual inspection of the individual plots showed total IGF-1 levels are remarkably 
stable over time in EDTA complemented whole blood (figure 1A). Remarkably, most 
pronounced variation in EDTA samples occurred at early blood processing delays of 2 
and 8 h. Individual increments of IGF-1 in EDTA plasma did not exceed 9% at all time-
points, except in one sample which had 13-22% change over all time-points, including 
early time-points. By paired t-test, in EDTA plasma no significant differences from the 
reference value were found up till 7 days processing delay. The individual time-effect 
curves, confirmed by LME analysis, show that total IGF-1 levels are stable in EDTA 
complemented whole blood over several days (b = 9.3*10-⁴, se = 6.9*10-⁴, p = 0.18).
IGF-1 levels in serum and heparin whole blood (figures 1B–C), on the other hand, 
were significantly different at all delayed time-points (paired t-test), except for serum 
samples with a 2-hr delay. After 24 h delay, individual increments averaged 15 ± 6% in 
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serum and 17 ± 6% in heparin samples and increased further to 40 ± 8% in serum and 
47 ± 10% in heparin samples. LME analyses confirmed that IGF-1 levels in serum and 
heparin increased significantly over time (Serum IGF-1 b = 1.5*10-³, se = 5.3*10-³, p 
= 0.006; Heparin IGF-1 b = 0.026, se = 3.6*10-³, p = 0.0008).
IGFBP-3 levels showed more variation between measurements and less consistent 
effects, as can be seen in the plots of EDTA, serum and heparin samples (figures 1D–F). 
Serum samples with 2 h, 24 h and 14 days processing delay were significantly different 
from the reference value. In heparin and EDTA, significant differences were found 
starting from 72 h processing delay. LME analysis showed a trend to decreasing values 
in heparin and serum (Serum IGFBP-3 b = − 1.6*10-³, se = 3.4*10-⁴, p = 0.0001; 
Heparin IGFBP-3 b = − 7.9*10-⁴, se = 2.2*10-⁴, p = 0.008), and marginal stability in 
EDTA plasma (b = 4.5*10-⁴, se = 2.3*10-⁴, p = 0.06).
Table 1. Examples of Reported Blood Products and Blood Processing Times Used for IGF-1 and 
IGFBP-3 Measurements in Large Multi-Center Studies
Discussion
In this study we evaluated whether IGF-1 and IGFBP-3 are sufficiently stable in whole 
blood samples stored at room temperature to justify delay in blood processing. Total 
IGF-1 and IGFBP-3 levels remained stable in whole blood samples with EDTA up to 
7 days. Stability of IGF-1 and IGFBP-3 levels in non-EDTA treated whole blood could 
not be shown. IGF-1 levels increased with blood processing delay times in serum and 
most plainly in heparin samples.
As endogenous protease activity and blood cell metabolism are continuous processes in 
collected blood samples, changes in protein levels in whole blood samples can occur by 
proteolysis or release of factors by blood cells. Acid pH conditions and proteolysis of 
IGFBP-3 in the samples can dissociate the complex of IGF-1 with IGFBP-3 and the 
acid-labile subunit (ALS). Furthermore, growth factors such as IGF-1 can be released 
by activated or dying and lysed blood cells [6]. In this study, we were able to directly 
compare the influence of blood carrier medium on the stability of IGF-1 and IGFBP-3 
in whole blood. Addition of the anticoagulant EDTA did increase stability of IGF-1 
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and IGFBP-3, it is therefore likely that EDTA reduces these processes of proteolysis 
of proteins, and activation or lysis of blood cells. EDTA is added to blood samples 
to block the coagulation cascade by inhibiting calcium-dependent proteases, among 
which there are several proteases described to be capable of cleaving IGFBP-3 [3]. 
Interestingly, one prior study suggested and confirmed that addition of a protease 
inhibitor (aprotinin) can increase stability of IGF-1 in whole blood [7].
In this study, samples were kept in an airconditioned laboratory at room temperature, 
allowing for slight variations in temperature. Our study was designed to show sample 
stability under less stringent conditions, that would permit delayed processing of 
unrefrigerated samples. Potential differences in climate and laboratory temperature 
control between centres were not covered in our study. However, we expect the 
biochemical effect of ambient variations in temperature on sample stability to be minor 
to the effect of blood processing delay.
A small number of studies have evaluated the stability of total IGF-1 and IGFBP-3 
levels in whole blood specimens under varying conditions and in various blood carrier 
mediums. Ellis et al. reported stability in EDTA treated blood samples that were kept 
at room temperature for up to 24 h [8], a finding that is confirmed and extended to 
longer time-spans in our present study. A study by Kristal et al. [9], however, found 
decreased levels of IGF-1 (up to 5.7%) and IGFBP-3 (up to 2.9%) in partly refrigerated 
EDTA blood samples of 40 individuals after processing delays of 32 to 144 h. They 
concluded that processing delays longer than 32 h have small but significant effects on 
IGF-1 and IGFBP-3.
Increases in IGF-1 and IGFBP-3 levels in serum whole blood stored at room temperature 
were previously reported by Harris et al. [10]. They found significant increases within 
24 h delay. Stability of IGF-1 and IGFBP-3 in heparinised whole blood up to 36 h was 
claimed by Hankinson et al. [11], but these results were not described in further detail.
Our study has implications on the desired sample collection in large multi-center 
cohort studies on epidemiological implications of IGF-1 and IGFBP-3. The use of 
different blood specimens and the duration of the blood processing delays vary much 
among these large multi-center studies (table 1). They include the use of serum and 
heparin samples with delays that in the present study are shown to result in significantly 
changes in measured IGF-1 and IGFBP-3 levels [11-14].
Our results show that EDTA supplemented whole blood is the preferred carrier 
medium for IGF-1 and IGFBP-3 measurements when prolonged processing delays 
are anticipated. Total IGF-1 and IGFBP-3 levels are stable in whole blood with 
EDTA at room temperature for up till 7 days. Delayed blood processing, however, 
could significantly affect the results in studies using IGF-1 measurement in serum or 
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heparin samples. Based on our study we conclude that levels of IGF-1 and IGFBP-3 
are sufficiently stable in whole blood with EDTA to justify transport and delayed blood 
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Abstract
High circulating insulin-like growth factor 1 (IGF-1) levels are firmly established as 
a risk factor for developing breast cancer, especially estrogen positive tumors. The 
effect of circulating IGF-1 on prognosis once a tumor is established is unknown. The 
authors explored the effect of IGF-1 blood levels and of its main binding protein, 
IGFBP-3, on overall survival and occurrence of second primary breast tumors in breast 
cancer patients, as well as reproductive and lifestyle factors that could modify this risk. 
Patients were accrued from six hospitals in the Netherlands between 1998-2003. Total 
IGF-1 and IGFBP-3 were measured in 582 plasma samples. No significant association 
between IGF-1 and IGFBP-3 plasma levels and overall survival was found. However, in 
a multivariate cox regression model including standard prognostic variables high IGF-
1 levels were related to worse overall survival in patients receiving endocrine therapy 
(HR = 1.37, 95% CI: 1.11, 1.69, P 0.004). These data at least indicate that higher 
IGF-1 levels, and as a consequence most likely IGF-1-induced signaling, are related to 
a less favorable overall survival in breast cancer patients treated with endocrine therapy. 
Interventions aimed at reducing circulating levels of IGF-1 in hormone receptor 
positive breast cancer may improve survival.
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Introduction
Interaction of Insulin-like growth factor 1 (IGF-1) with its key receptor, the IGF-
1 Receptor (IGF-1R), gives strong proliferation and survival signals [1,2]. Ample 
evidence has solidly implicated this tyrosine kinase receptor system in growth and 
survival of cancer cells [3]. Antibodies and tyrosine kinase inhibitors targeting the IGF-
1R have been developed and their activity in multiple tumor types is now being tested 
in clinical trials [4]. 
A group of six IGF-binding proteins (IGFBPs) exist, that modulate IGF-1 actions, by 
regulating stability of IGF-1 in the circulation, transport of IGF-1 to target tissues and 
interaction with the receptors [5]. Besides the regulatory effects on IGF-1 functions, 
IGFBPs have been shown to exhibit IGF-1 independent actions, such as growth 
inhibition and apoptosis. Strong anti-apoptotic properties have been attributed to 
IGF-1s main binding protein IGFBP-3 [6]. 
IGF-1 plays a central role in integrating signals of nutrition and stress into energy 
shifts from energy-expensive anabolic processes, such as growth and reproduction, 
to preserving responses under catabolic or otherwise demanding circumstances, such 
as DNA damage [7,8]. Executing both metabolic and reproductive functions IGF-
1 closely interacts with insulin and steroid hormones [4]. Also, apart from being 
genetically determined, IGF-1 and IGFBP-3 levels are believed to be influenced by 
anthropometric, reproductive, lifestyle, and dietary factors. Thus, IGF-1 is seen as 
a potential factor linking known influences of steroid hormones, body weight, fat 
metabolism, and insulin on cancer with each other. 
High IGF-1 levels are by now a well-established risk factor in women for developing 
breast cancer [9,10]. A collaborative analysis of 17 prospective studies confirmed this 
finding and found that the association is not substantially modified by IGFBP-3, and 
seems to be confined to estrogen-receptor-positive tumors [11]. Biological ground 
for a causal relationship between IGF-1 levels and tumorigenesis comes from animal 
models. IGF-1 deficient mice show reduced growth and metastasis of tumors and 
xenografts and increased resistance to carcinogen-induced tumorigenesis [3]. Vice versa, 
transgenic overexpression of IGF-1 in basal epithelial cells induced well-differentiated 
adenocarcinomas [12,13]. The IGF-1R is overexpressed in many breast tumors and 
several IGF-1R inhibitors have recently entered clinical trials [4]. 
However, the effects of circulating IGF-1 and IGFBP-3 on disease recurrence and survival 
in breast cancer survivors are understudied. Four previous studies have investigated 
IGF-1 and prognosis in breast cancer patients, with varying patient numbers and study 
designs. These studies have shown inconsistent results. While associations of IGF-1 
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levels with decreased survival are found, these findings were not uniformly confirmed 
by others or are attributed to a confounding effect of tamoxifen use [14-16, 21].  
We hypothesized that high circulating levels of IGF-1 or low levels of IGFBP-3, 
through proliferative and anti-apoptotic effects, would be associated with an increased 
risk of second primary breast tumors and decreased overall survival in breast cancer 
patients. In a large cohort of breast cancer patients, with available plasma samples, 
clinical outcome parameters and reproductive history, we explored the effect of IGF-1 
and IGFBP-3 levels on overall survival, occurrence of second primary breast tumors 
and environmental factors that could modify this risk. 
Materials and methods
The study cohort consists of 1851 breast cancer patients, enrolled between 1998-2003 in 
a study designed to investigate low-penetrance genetic mutations predisposing to breast 
cancer [17,18]. Patients were accrued from six hospitals in the northern Netherlands 
(the University Medical Center in Groningen, and Medical Centers in Leeuwarden, 
Harlingen, Drachten, Dokkum and Sneek). In Drachten and Dokkum, breast cancer 
patients were identified through the regional cancer registry (Comprehensive Cancer 
Center Northern Netherlands). In the other hospitals, all breast cancer patients visiting 
the outpatient clinic for follow-up visits over a 1-year period were asked to participate 
by their physician. No selection was performed, only patients with a known BRCA1 or 
BRCA2 mutation were excluded. 
Data on (self-reported) reproductive factors, height and weight, prior history of cancer, 
family history of cancer, smoking history and alcohol consumption were collected 
using questionnaires. Records on patient and tumor characteristics were updated and 
managed by the regional cancer registry. Follow-up was performed according to the 
regional follow-up guidelines (www.iknl.nl/page.php?nav_id=298&id=443) via the 
cancer registry. The mean follow-up period was 5.5 years (SD ± 2 years). Endpoints for 
the present study were overall survival and occurrence of second primary breast tumors. 
Overall survival is specified as death from any cause. No information on cause of death 
is available in the cancer registry dataset. Second primary breast tumors were defined 
as contralateral breast tumors, excluding local recurrences. The resulting time variables 
were calculated as time from diagnosis to the specified endpoints. 
Indication for adjuvant treatment and selection of type of treatment was rule-based 
according to national treatment guidelines of the Dutch Association of Comprehensive 
Cancer Centers (www.oncoline.nl). Briefly, breast conserving surgery with axillary lymph 
node dissection was indicated for tumors <4 cm, complemented with radiotherapy to 
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the breast. Alternatively, a modified radical mastectomy was performed. Loco-regional 
radiotherapy, consisting of parasternal, axillary, infra and supra-clavicular nodal 
irradiation, was indicated in case of >3 positive axillary nodes or extranodal growth. 
Pre-menopausal node-positive patients received adjuvant chemotherapy, generally 
consisting of cyclophosphamide, methotrexate and 5-fluorouracil. Anthracycline-
based chemotherapy was increasingly used for high-risk patients since the mid-1990s. 
Adjuvant systemic therapy was also administered to node-negative patients with 
intermediate or poorly differentiated tumors larger than 1,1 cm. Furthermore, all 
hormone-receptor positive, node-positive and unfavorable node-negative patients were 
to receive 5-years tamoxifen, irrespective of menopausal status. Inoperable and locally 
advanced cancers received chemotherapy, hormonal therapy and/or radiotherapy.
All samples and data in this study were anonymized and individuals were aware that 
they would not be informed about individual test results. All included patients gave 
written informed consent at enrollment in the study and 1566 out of 1851 patients 
had specified their consent for future studies. The Medical Ethical Committees of the 
participating hospitals approved the study.
Non-fasting 20-mL EDTA (ethylene diamine tetra-acetic acid) blood samples were 
collected at enrollment at the recruiting hospital or at the patient’s home. Samples 
were delivered overnight by blood bank transportation running daily. On receipt at 
our laboratory, samples were kept in an air-conditioned laboratory at a temperature 
of approximately 20°C, unopened and sheltered from direct sunlight until blood 
processing. Blood processing was done in clusters, delays until blood processing ranged 
from 2-5 days. Plasma samples were stored separately in small aliquots at −80 °C until 
time of analysis. Stability of IGF-1 and IGFBP-3 in EDTA plasma samples at room 
temperature with blood processing delays up to 7 days has been shown previously [19]. 
Owing to budgetary restrictions, total IGF-1 and IGFBP-3 were measured in 584 
available plasma samples by automated chemiluminescence assay using Immulite 
system and reagents (Siemens Diagnostics, Los Angeles CA, USA). Two samples were 
lost for analysis due to a technical error. Samples had been collected within six years 
post-diagnosis (median 2 years). Intra- and interassay variability were estimated at two 
concentrations in at least 10 runs and two repetitions per run. Intra- and interassay 
variability of IGF-1 measurements were 1.7% and 2.1%, respectively, measured at 
8.76 nmol/L, and 1.7% and 1.2% at 28.83 nmol/L. Intra- and interassay variability 
of IGFBP-3 measurements were 2.0% and 2.7%, respectively, measured at 0.94 µg/
mL, and 2.7% and 1.0%, at 3.99 µg/mL. IGF-1 and IGFBP-3 concentrations showed 
a Gaussian distribution in our study population, overall and by hormonal treatment 
(Suppl. Fig. 1). The molar ratio IGF-1:IGFBP-3, used to estimate the biologically 
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active fraction of IGF-1, was calculated based on the following conversion: 1 ng/ml 
IGF-1 equals 0.130 nM, 1 ng/ml IGFBP-3 equals 0.036 nM.
Table 1. Patient and Tumor Characteristics, Received therapy, Follow-up, Reproductive and Lifestyle 
Factors.
To exclude therapy-effects on IGF-1 and IGFBP-3 levels, IGF-1 and IGFPB-3 
levels were measured prospectively in a separate cohort of breast cancer patients at 
our institution (n=29) receiving adjuvant systemic chemotherapy and hormonal 
therapy [20]. Plasma samples were collected at diagnosis, one month after cessation of 
chemotherapy (FEC) and one month after start of endocrine therapy with Tamoxifen. 
No effect of chemotherapy on IGF-1 and IGFBP-3 levels was observed. IGF-1, but not 
IGFBP-3, levels decreased significantly during Tamoxifen treatment (data not shown), 
which is in line with previous reports [21-25]. Analyses including IGF-1 levels were 
subsequently performed separately in patient groups receiving endocrine therapy or 
not.
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Data analysis was performed using the SPSS 16.0 statistical package (SPSS inc., 
Chicago, IL, USA). Associations of patient and tumor characteristics (age at diagnosis, 
menopausal status at diagnosis, tumor size, axillary lymph node status, distant metastases, 
received surgical therapy, radiotherapy, chemotherapy and hormonal therapy), 
reproductive and lifestyle factors (age at menarche, age at first childbirth, number of 
children, breastfeeding, use of oral contraceptives, body mass index (BMI), cigarette 
smoking and alcohol consumption) with IGF-1 and IGFBP-3 levels, respectively, were 
tested using univariate linear regression analysis. Associations of patient and tumor 
characteristics, reproductive and lifestyle factors and levels of IGF-1 and IGFBP-3 with 
occurrence of second primary breast tumors were analyzed using logistic regression 
analysis. Associations of available parameters with overall survival (OS) were analyzed 
using univariate and multivariate Cox regression analysis. Additionally, effects of IGF-
1 and IGFBP-3 on OS were estimated using standard prognostic variables, regardless 
of their statistical significance. All reported P values are 2-sided. Adjustment for 
potential confounding factors, such as time between breast cancer diagnosis and sample 
collection, was achieved by including potential confounders into multivariate models.
Results 
Patient and tumor characteristics are summarized in Table 1. Median IGF-1 level was 
18.2 nmol/l (range 3.2 – 48.4), median IGFBP-3 level was 4.36 µg/ml (range 1.26 – 
8.50). IGF-1 levels were higher in patients not receiving hormonal therapy (n=426, 
median 19.3 nmol/l (range 3.7 – 48.4)) compared to patients receiving hormonal 
therapy (n=156, median 14.3 nmol/l (range 3.2 – 42.0)) (P < 0.001). IGFBP-3 levels, 
as expected, were not different according to received hormonal therapy. IGF-1 and 
IGFBP-3 were significantly related to each other (B = 3.37 (SE 0.23), P < 0.001).  
IGF-1 and IGFBP-3 levels were lower at higher ages at diagnosis and postmenopausal 
status. IGFBP-3 levels were lower at higher age at menarche. IGF-1 levels were lower at 
higher BMI. Chemotherapy, alcohol consumption and use of oral contraceptives were 
related to higher IGF-1 and IGFBP-3 levels (Table 2A-B). 
A second primary breast tumor was found in 21 patients (3.6%) and IGF-1 and 
IGFBP-3 levels did not influence the occurrence of second primary breast tumors in 
our analysis (IGF-1: OR = 1.03, 95% CI: 0.97, 1.09, P 0.36; IGFBP-3: OR = 0.94, 
95% CI: 0.61, 1.44, P 0.78).  
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Older age, postmenopausal status, higher BMI, positive axillary nodal status, higher 
differentiation grade, tumor size, received hormonal therapy and chemotherapy were 
related to shorter OS, while use of oral contraceptives and higher IGFBP-3 levels 
(HR = 0.66, 95% CI: 0.47, 0.98, P 0.003) were related to a favorable OS (Table 3). 
Table 2B Significant Associations of Patient and Tumor Characteristics with IGFBP-3 Levels 
(univariate linear (unstandardized B (SE)) and logistic regression (OR (95%CI), P value)






































































Comparable direction and magnitude of the association of IGFBP-3 with OS were 
seen both in patients treated with and without adjuvant hormonal therapy (hormonal 
therapy: HR = 0.67, 95% CI: 0.41, 1.08, P 0.1, no hormonal therapy: HR = 0.68, 
95% CI: 0.47, 0.98, P 0.04), although not consistently statistically significant, most 
likely due to lower numbers in the patient group treated with hormonal therapy, and 
thus reduced power.
No significant effect of IGF-1 levels on OS was found (HR = 0.96, 95% CI 0.92, 1.01, 
P 0.09), neither in the subgroup of patients with (HR = 1.02, 95% CI: 0.95, 1.09, P 
0.6) nor without (HR = 0.96, 95% CI: 0.90, 1.01, P 0.1) hormonal therapy. The molar 
ratio IGF-1:IGFBP-3 did not contribute to prognostic effects.
Multivariately, differentiation grade and distant metastases were independent prognostic 
factors for overall survival. IGFBP-3 was not independently related to overall survival 
(Table 4). Analyses including standard prognostic variables showed that high IGF-1 
levels were related to worse overall survival in patients treated with hormonal therapy 
(HR = 1.37, 95% CI: 1.11 – 1.69, P 0.004) (Table 5). 
Discussion
In a large prospective cohort of breast cancer patients, we found no significant 
association between IGF-1 and IGFBP-3 plasma levels and overall survival. In patients 
treated with hormonal therapy, however, an unfavorable effect of IGF-1 on overall 
survival became evident after adjustment for age and other traditional prognostic 
variables, including tumor stage, grade, and lymph node involvement. Several other 
correlations of reproductive and lifestyle factors with IGF-1 and IGFBP-3 levels were 
found (menopausal status, BMI, alcohol consumption, use of oral contraceptives, age 
at menarche), but these factors did not modify the risk associations. None of the studied 
reproductive or lifestyle factors, neither the focus parameters IGF-1 and IGFBP-3, was 
associated with occurrence of second primary breast cancer.  
A previous prospective study with comparable patient numbers and events (512 
patients, 45 events of death) and a similar distribution of prognostic parameters (age, 
tumor size, grade of differentiation) could not show a prognostic contribution of IGF-
1 plasma levels in early-stage breast cancer [14]. An association of IGF-1 on higher risk 
of recurrence was found in the WHEL study, a nested case-control study including 510 
cases of breast cancer recurrence and 510 controls [15]. This effect, however, did not 
reach significance and was lost when stratifying for tamoxifen use and was thought to 
be attributed to known IGF-1 reducing effects of tamoxifen. 
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Both studies reported a higher rate of adjuvant treatment with chemotherapy and 
hormonal therapy in their patient population.     
Serum IGF-1 was higher, although not significant, in patients with local or distance 
recurrences of breast cancer in a smaller-sized prospective cohort of 110 postmenopausal 
breast cancer patients, including 32 either local, distal or contralateral recurrences 
[16]. In a prevention trial of fenretinide, a synthetic retinoid derivative, high baseline 
circulating IGF-1 and low IGFBP-3 among controls were associated with occurrence 
of a second breast malignancy. Fenretinide reduced the risk on second breast cancer, 
but this clinical effect could only marginally be attributed to the decline in IGF-1 level, 
that occurred simultaneously [26]. Taken together, invariably weak positive hazard 
ratios are found in cohort studies, including our current investigation, to describe the 
effect of circulating IGF-1 levels on prognosis among breast cancer survivors. 
A major limitation of our present study is a low number of events during the follow-
up period, 6% and 12% for occurrence of second breast cancer and overall survival, 
respectively. Results of the multivariate analysis in patients treated with hormonal 
therapy are based on no more than 13 events. Patients were included into the study 
during their regular follow-up schedule on average 2.6 years after diagnosis, suggesting 
a selection bias in favor of patients with a mild course of disease. Available survival data 
did also not allow analysis specifically of breast cancer related survival. 
Potential confounders that could not be traced in our database included co morbidities, 
such as diabetes, and the actual treatment schedule at the time of blood collection.
Analogue to increased risk of IGF-1 on estrogen-receptor-positive breast cancer 
development, high IGF-1 levels may be associated with breast cancer progression in 
hormone receptor positive tumors. This hypothesis is supported by the knowledge that 
cross-talk between the IGF-1 receptor and the estrogen receptor results in synergistic 
growth in breast cancer cells [27]. As effective anti-estrogen treatment for hormone 
receptor positive tumors lowers IGF-1 concentrations, persistent high IGF-1 levels in 
thus treated patients may correlate with failure or resistance to endocrine treatment. 
Indeed, modulations of the IGF-1 axis have been implicated in development of 
resistance to endocrine therapies [28-30]. Interestingly, an IGF-1 activated gene 
transcription signature was found in breast tumors and in ER positive tumors this 
signature was connected to poor prognosis, suggesting that circulating IGF-1 could 
locally act on tumors by activating gene transcription profiles leading to e.g. tumor 
progression or hormone independence [31].
In our study, the estrogen receptor status of tumors itself was not available. From the 
prevailing guidelines at the study period, it can be deduced that all patients in our 
study group receiving tamoxifen had hormone-receptor positive tumors that were 
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either node-positive or unfavorable node-negative tumors. Contrary, both hormone 
receptor negative tumors and hormone receptor positive, node-negative tumors may 
have been present in the group of patients receiving no hormonal treatment. 
Caution is therefore warranted with interpretation of the finding that high IGF-1 
levels were related to worse overall survival in patients treated with hormonal therapy 
specifically. Moreover, non-adherence rates to adjuvant hormonal therapy are reportedly 
as high and variable as 10-85 per cent [32], raising concern whether failure of reduction 
of IGF-1 levels by tamoxifen might be a measure of non-adherence to drug therapy in 
a subset of cases. 
A recent trial which randomly assigned postmenopausal breast cancer patients to 5 
years of tamoxifen 20 mg daily or tamoxifen plus 2 years of octreotide as adjuvant 
therapy was unsuccessful in showing a reduction in risk of breast cancer recurrence 
by down-regulating IGF-1 levels [33]. Major draw-back of this study was a limited 
tolerance of octreotide treatment caused mainly by symptomatic gallstone disease, 
which necessitated a reduction of the duration of octreotide use. Nevertheless, the 
result was disappointing for the IGF-1R pathway inhibition as a therapeutic target in 
ER-positive breast cancer. 
In conclusion, our study found no association between IGF-1 concentrations and all-
cause mortality at the bivariate level when stratified by hormonal therapy use. However, 
our multivariate analysis may indicate a connection of high IGF-1 levels with worse 
overall survival in breast cancer patients treated with hormonal therapy. Interventions 
aimed at reducing circulating levels of IGF-1 levels combined with endocrine therapy 
may improve breast cancer survival, but have till now been unsuccessful. Future 
investigations should be directed at exploring if high IGF-1 levels or an absent or 
modest drop in IGF-1 levels in response to hormonal treatment are a measure of failure 
of endocrine therapy. 
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Treatment of breast cancer cells by IGF-
1R tyrosine kinase inhibitor combined 
with conventional systemic drugs
Abstract
Insulin-like growth factor-1 receptor (IGF-1R) is a tyrosine kinase receptor mediating 
cell growth and survival of cancer cells. We studied responses to IGF-1R tyrosine kinase 
inhibitor NVP-AEW541 combined with conventional systemic drugs in breast cancer 
cell lines of different clinical subtype. Sensitivity to NVP-AEW541, single treatment 
and combinations with tamoxifen, trastuzumab, doxorubicin or paclitaxel, was tested 
in MCF7, SKBR3 and T47D cells. Cells were assayed for proliferation, cell death, cell 
cycle distribution and phosphorylation of proteins downstream of IGF-1R. Treatment 
of NVP-AEW541 resulted in reduced proliferation, G-1 cell cycle arrest and reduced 
phosphorylation of protein kinase B (AKT) and extracellular-signal-regulated protein 
kinase (ERK). Sensitivity to IGF-1R tyrosine kinase inhibition was low in T47D cells, 
despite their high IGF-1R expression. NVP-AEW541 combined with trastuzumab had 
synergistic cytotoxic effects in T47D cells, and additive effects were shown in MCF7 
and SKBR3 cells. Also, combination with doxorubicin had antagonistic effects in 
T47D cells. Doxorubicin caused up-regulation of phosphorylated ERK in T47D cells, 
which was not inhibited by NVP-AEW541. Antagonistic effects should be anticipated 
when IGF-1R inhibitors are combined with conventional systemic drugs in a subset 
of breast tumors. Development of functional biomarkers predicting tumor response to 
tailored IGF-1R therapy is warranted. 
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Introduction
Interaction of insulin-like growth factor 1 with its key receptor IGF-1R gives strong 
proliferation and survival signals [1, 2]. Ample evidence has implicated dysregulation of 
IGF-1R signaling in tumor development and progression [3]. Currently, development 
of drugs targeting the IGF-1R as anticancer treatment is emerging. Antibodies targeting 
the IGF-1R have been developed and their activity in multiple tumor types is now 
being tested in clinical trials [4]. For example, single-agent activity of figitumumab, a 
humanized monoclonal antibody directed against IGF-1R, has been successfully tested 
for treatment of Ewing’s sarcoma [5]. IGF-1R functions as a ligand-activated tyrosine 
kinase receptor. Upon ligand binding, a conformational change induces activation of 
the kinase. Several docking proteins, such as SRC homology 2 domain-containing 
(SHC) protein and insulin receptor substrates (IRS1-4), are subsequently recruited to 
the phosphorylation sites in the cytoplasmic domain. Then the signal is propagated 
through the phosphatidylinositol-3-kinase (PI3-Kinase)/AKT and mitogen-activated 
protein (MAP) kinase pathways resulting in cell proliferation and inhibition of apoptosis 
[6]. IGF-1R signaling can also induce differentiation, malignant transformation and 
regulate cell–cell adhesion [2]. A dynamic downstream signaling network of different 
phosphorylation sites of the receptor and cell context specific recruitment and activation 
of signaling molecules regulates these different functions [7-9]. Furthermore, IGF-
1R can interact with steroid hormones and their receptors, other peptide growth 
factor receptors, such as human epidermal growth factor (HER) family of receptors, 
and is intimately connected to the metabolic functions of insulin through a shared 
structural homogeneity to the insulin receptor (IR), allowing formation of IGF-1R/
IR hybrid receptors [10-15]. Following successful introduction of small-molecular 
weight inhibitors of related receptor tyrosine kinases, such as erlotinib, gefitinib and 
lapatinib, for anticancer therapy [16], tyrosine kinase inhibitors are being developed 
selectively targeting IGF-1R, among them NVP-AEW541 [17]. Specificity of tyrosine 
kinase inhibitors of IGF-1R versus IRs has been an issue. Previous studies showed 
that NVP-AEW541 inhibits tumor growth in vitro and in vivo in a panel of solid and 
hematological tumors, alone and in combination with chemotherapeutic drugs [17, 
18]. Studied efficacy of this agent has been extended to panels of breast cancer cell 
lines, however, translation of responses to IGF-1R targeted tyrosine kinase inhibitors 
in various breast cancer cell lines into clinically applicable approaches has proven to 
be difficult [19-22]. The mainstay of systemic adjuvant and non-adjuvant treatment 
for breast cancer nowadays includes anthracycline- and taxane-based chemotherapy, 
hormonal therapy with tamoxifen and/or aromatase inhibitors for hormone receptor-
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positive tumors, and targeted therapy, mostly with the HER2 antibody trastuzumab, in 
HER2-positive tumors [23]. We studied responses to IGF-1R tyrosine kinase inhibitor 
NVP-AEW541 in different clinical subtypes of breast cancer cell lines, expressing 
contrasting levels of the estrogen receptor, HER2 and IGF-1R, and tested combinations 
with conventional systemic drugs. 
Materials and Methods
Cell lines. The human breast carcinoma cell lines MCF7, SKBR3 and T47D were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). 
MCF7 and T47D are hormone receptor-positive cell lines. SKBR3 is an HER2-
positive, hormone receptor-negative cell line. MCF7 and T47D were grown in Roswell 
Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal calf 
serum (FCS), SKBR3 was grown in Dulbecco’s modified eagle’s medium (DME)-high 
supplemented with 10% FCS. The cells were routinely passaged twice a week. Cells 
grown in monolayer to 80% confluence were detached by 5 min trypsin treatment 
(Trypsin 0.025%, 1 mM EDTA) and resuspended in appropriate dilutions in culture 
medium. Assays were performed in culture medium with lower serum concentrations, 
1% FCS for MCF7 and SKBR3, 5% FCS for T47D. 
Quantification of IGF-1R, HER2 and epidermal growth factor receptor (EGFR) 
membrane expression. Cells were seeded in 3 ml culture medium supplemented with 
10% FCS in 6-well plates. At day 1, the culture medium was replaced by low serum-
containing medium (see above) with or without NVP-AEW541 (0.5-5 µM, stock 
solution 10 mM in DMSO) (gift from Novartis Pharma AG, Basel, Switzerland) and 
incubated for another 24 or 72 hours. Cells were harvested at 70-80% confluency, 
resuspended and assayed by fluorescence-activated cell sorting. Analysis of IGF-1R, 
HER2, and EGFR membrane expression was performed using a flow cytometer (Epics 
Elite; Coulter Electronics, Hialeah, FL, USA; and FACScalibur; Becton Dickinson 
Medical Systems, Sharon, MA, USA). For IGF-1R, phycoerytrocin (PE)-conjugated 
mouse anti-human IGF-1Rα (BD Biosciences Pharmingen, San Jose, CA, USA) was 
used, and PE-conjugated mouse IgG₁,κ (BD Biosciences Pharmingen) was taken as 
an isotype control. For HER2 detection trastuzumab (humanized IgG1 monoclonal 
antibody against HER2; Genentech, San Francisco, CA, USA) and for EGFR detection 
cetuximab (humanized monoclonal antibody against EGFR; Merck, Darmstadt, 
Germany) were used as primary antibodies, followed by incubation with fluorescein 


































































































































Figure 2. Sensitivity to NVP-AEW541 as measured by 3-(4,5 dimethylthiazol-2yl)-2,5- diphenyltetra-
zolium bromide (MTT) assay, mean±SEM (n=4).
FITC-conjugated anti-human IgG antibody alone was taken as an isotype control. 
Membrane expression was determined by subtracting the mean fluorescent intensity 
(MFI) of the isotype control from the MFI in presence of the detection antibody. 
Comparisons were made by paired Student’s t-test. 
Cytotoxicity assay. Sensitivity of MCF7, SKBR3 and T47D to NVP-AEW541 was tested 
with 3-(4,5 dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Prior 
to the experiments, the optimal cell density was assessed to ensure exponential growth 
of cells at 96 hours in 96-well microculture plates in conditions of low serum culture 
used for the experiments. For the experiments, MCF7 and T47D cells were seeded 
at 5,000 cells per well and SKBR3 at 7,500 cells per well into 96-well flat-bottom 
cell culture plates. NVP-AEW541 (1-10 µM), as single treatment, or combined with 
trastuzumab (1-100 µg/ml), paclitaxel (1-4 nM), or doxorubicin (5-50 nM), was added 
after attachment of the cells to the culture plate. 
Tamoxifen (0.5-2 µM) was combined with NVP-AEW541 for MCF7 and T47D 
cells and cetuximab (0.5-50 µg/ml) was combined with NVP-AEW541 for T47D 
and SKBR3 cells. Furthermore, cells were treated with IGF-1 (1-500 ng/ml; Abcam, 
Cambridge, UK) and IGF-1R neutralizing (mouse monoclonal) antibody alphaIR-3 
(0.125-1.0 µg/ml, Abcam). 
In cases of combined treatment, both drugs were added simultaneously and cells were 
exposed continuously to the drugs. All experiments were performed in quadruplicates 
and confirmed in at least three independent experiments. The percentage of cell 
survival was calculated by dividing the mean of the treated samples by the mean of the 
untreated sample, after subtraction of background extinction. The concentration of 
NVP-AEW541 single treatment yielding 50% inhibition (IC₅₀ values) were calculated. 
Treatment effects of combined treatments were calculated as follows: Enhancement 
ratio(ER)=(Survival(modulator+NVP-AEW541)/Survival(modulator)×100)/
Survival (NVP-AEW541). Outcomes of ER≤0.8 were considered synergistic, ER≥1.2 
antagonistic, and intermediary values, additive effects [24]. 
Trypan blue cell counts and analysis of apoptosis. In parallel, cells were seeded and 
treated as described for caspase activity assay and trypan blue cell counts (0.5 ml total 
volume, 24-well plates). At the designated time points, cell numbers and viability of 
harvested cells, resuspended in the collected supernatant, were assessed by trypan blue 
exclusion. This experiment was performed in duplicate and every sample was counted 
twice. Results are expressed relative to the number of initially seeded cells. Activity of 
caspase-3 and -7 after exposure to NVP-AEW541 for 24 and 72 hours was determined 
using the fluorescence peptide substrate Ac-DEVD-AFC (Sigma-Aldrich, Zwijndrecht, 
the Netherlands), according to the manufacturer’s instructions. Relative caspase-3/-7 
activity was expressed as the ratio of that of treated to untreated cells. Staining with 
acridine orange was used as well to distinguish apoptotic cells from vital cells in SKBR3 
and T47D cells. 
Cell cycle analysis. Exponentially growing cells were harvested and washed in phosphate 
buffered saline (PBS), and then fixed and permeabilized by ice-cold ethanol. Cells were 
stored at 4°C for up to 48 hours. Prior to the addition of propidium iodide (PI), the 
cells were washed and incubated with RNAse for 15 min at room temperature. After 
PI incubation, the DNA content of at least 5,000 cells was measured by flow cytometry 
and analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA). 
Differences in cell cycle distribution between treated and untreated samples were 
analyzed by Chi-square test. 
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Figure 3. A: Dose-dependent reduction of S-phase fraction in MCF7 cells after 72 hour treatment 
with NVP-AEW541 (n=3). *p-value 0.002, χ2-test. B: Synergistic reduction of S-phase fraction by 
concurrent treatment of T47D cells with NVP-AEW541 and trastuzumab (100 µg/ml). C: Effect on 
cell cycle distributions of concurrent treatment of T47D cells with NVP-AEW541 (5 µM) and doxo-
rubicin (25 nM).
Western blot analysis. 
To determine phosphorylation status of the IGF-1R and downstream proteins AKT 
and ERK, cells were cultured in 6-well plates to a confluence of 70% in culture media 
supplemented with 10% FCS. Cells were then serum starved for 8 hours and treated 
with IGF-1R inhibitor NVP-AEW-514 (2.5 µM) and the antibody alphaIR-3 (1 µg/
ml) for 10 min and 6 hours. Five minutes before harvesting, the cells were stimulated 
with 100 ng/ml IGF-1. Combination effects of doxorubicin and NVP-AEW541 
were determined by adding NVP-AEW541 at 2.5 µM 8 hours before or 8 hours after 
treatment with doxorubicin at 0.5 µM in culture media containing 1 and 5% FCS, 
respectively. Cells were harvested on ice, washed three times in ice-cold PBS and cell 
lysates were prepared with lysis buffer consisting of mammalian protein extraction 
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reagent (M-PER) with 1:100 Protease Inhibitor Cocktail and 1:100 Phosphatase 
Inhibitor (Pierce, Rockford, IL, USA). After determination of protein concentrations 
by Bradford analysis, cell lysates clarified of insoluble components were dissolved in 
sodium dodecyl sulfate (SDS)-sample buffer with 10% 2-β-mercaptoethanol to a final 
concentration of 1 µg/µL protein and boiled for 5 min. 
Figure 4. Insulin-like growth factor-1 receptor (IGF-1R) membrane expression (mean fluorescent 
intensity (MFI)) after 24-hour and 72-hour treatment with 2.5 µM NVP-AEW541 (n=4)
The samples were stored at −20°C until analysis. Equivalent amounts of cell lysate were 
separated by 10% SDS-polyacrylamide gel electrophoresis (1 hour 180 V; BioRad, 
Veenendaal, the Netherlands) and transferred to a polyvinylidene difluoride (PVDF) 
membrane (1 hour 250 mA; Immobilon-P; Millipore, Billerica, MA, USA). After 
appropriate washing and blocking of the membrane (TBS-tween-milk; Sigma Aldrich), 
focus proteins were detected by the respective antibody directed towards phospho p44/42 
MAPK (ERK) (thr202/204) E10 (mouse monoclonal, 1:2000 in TBS-t-milk), phospho 
AKT (ser473) (rabbit; 1:1000 in BSA), AKT (rabbit, 1:1000 in BSA), phosphorylated 
IGF-1R (tyr1135/1136)/IR (tyr1150/1151) (monoclonal rabbit, 1:1000 in BSA) 
(all: Cell Signaling, Danvers, MA, USA) and ERK-1 (k-23):sc-94 (polyclonal rabbit, 
1:800 in BSA; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and with overnight 
incubation at 4°C with 1:1000 chlorohexidine. A secondary horseradish peroxidase 
(HRP)-conjugated antibody directed to mouse (rabbit-anti-mouse) or rabbit (goat-
anti-rabbit) (1:1500 in TBS-t-milk; DakoCytomation, Glostrup, Denmark) was used 
and staining was performed with Lumilight Plus (western blotting substrate; Roche, 
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Almere, the Netherlands) or for actin staining BM chemiluminescence blotting 
substrate (POD; Roche). 
Results
Sensitivity to IGF-1R tyrosine kinase inhibition was tested in three breast cancer 
cell lines with different membrane expression levels of IGF-1R, HER2 and EGFR. 
MCF7 and T47D are hormone receptor positive cell lines, expressing high levels 
of IGF-1R. Whereas MCF7 expresses very low levels of HER2 and EGFR, T47D 
expresses intermediate levels of HER2 and EGFR; SKBR3 is an HER2-positive, 
hormone receptor-negative cell line, expressing low levels of IGF-1R and high levels 
of EGFR (figure 1). IGF-1 stimulation enhanced proliferation in MCF7 (60% at 
100 ng/ml), but not in SKBR3 and T47D. NVP-AEW541 reduced proliferation as 
measured by MTT assays in all tested cell lines in a dose-dependent manner (IC₅₀ 
MCF7=2.9±0.6 µM, SKBR3=4.9±0.4 µM, T47D=5.6±0.4 µM) (figure 2). This was 
confirmed by trypan blue cell counts; however, no significant effect on caspase activity 
as an indicator of apoptosis was shown. By acridine orange staining, small numbers of 
apoptotic cells were found: 12% in SKBR3 cells treated with 5 µM NVP-AEW541. 
Cell cycle distribution changed significantly on treatment with NVP-AEW541 with 
reduction of the S-phase fraction and increase of the G-0/G-1 fraction (figure 3A). 
IGF-1R membrane expression levels were significantly reduced by 20% after 24-hour 
treatment with 2.5 µM NVP-AEW541 in all cell lines. After 72-hour treatment, 
however, persistent receptor down-regulation was only seen in T47D cells (figure 4). 
The neutralizing anti-IGF-1R antibody alphaIR-3 did not have any substantial effect 
on cell survival of any of the cell lines. 
NVP-AEW541 combined treatment. NVP-AEW541 combined with trastuzumab had 
synergistic cytotoxic effects in T47D cells (ER=0.78±0.07, at doses of 5 µM and 100 
µg/ml, respectively). This combination also synergistically reduced the S-phase fraction 
(figure 3B). Additive effects were shown in SKBR3 and MCF7 cells. NVP-AEW541 
combined with doxorubicin had antagonistic effects in T47D cells (ER=1.75±0.26, 
at doses of 6 µM and 25 nM, respectively), irrespective of treatment sequence (figure 
5). Additive effects for NVP-AEW541 and doxorubicin were shown in SKBR3 and 
MCF7 cells. All other combinations tested revealed additive effects. On protein level 
(figure 6), phosphorylated IGF-1R/IR level was not measurable in SKBR3 and T47D 
cells (below detection limit), but was evident in MCF7 cells after IGF-1 stimulation. 
We found AKT phosphorylation was up-regulated by IGF-1 stimulation both 
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in MCF7 and T47D cells, as well as complete down-regulation of IGF-1 induced 
phosphorylated AKT in both cell lines in response to NVP-AEW541 and alphaIR-3 
after longer incubation times. In SKBR3 cells AKT was constitutively activated and 
not further up-regulated by IGF-1 stimulation, yet in response to NVP-AEW541, 
AKT was down-regulated. The ERK antibody detects pERK1 at p44 and, to a lesser 
extent, pERK2 at p42. 
Figure 5. Antagonistic effects of doxorubicin (25 nM) and NVP-AEW541 combinations in a 96-h 
MTT assay of T47D cells
In MCF7 cells both phosphorylated variants of ERK are up-regulated in response to 
IGF-1, and this up-regulation is only partially blocked by NVP-AEW541. In T47D 
and SKBR3 cells, an amount of constitutively active ERK2 exists. Upon IGF-1 
stimulation, strong up-regulation of phosphorylation of both variants of ERK occurs 
in T47D and only slightly in SKBR3 cells. In addition, in T47D cells NVP-AEW541 
more profoundly blocked IGF-1 induced ERK activation than in SKBR3 cells. 
Constitutive levels of pERK were not blocked. IGF-1 induced ERK activation was 
97
blocked by NVP-AEW541 more effectively in T47D compared to MCF7 cells (figure 
6). Doxorubicin caused a slight up-regulation of phosphorylated ERK in T47D cells 
and NVP-AEW541 did not inhibit this up-regulation. No significant effect of single 
treatment with doxorubicin or combined with NVP-AEW541 on phosphorylated 
AKT levels were seen (figure 7). Adding doxorubicin resulted in an enormous increase 
of cells arrested in G-2/M and S phases, to a degree in which proper fitting became 
inaccurate. Adding NVP-AEW541 resulted in a slight increase of cells in the G-0/G-1 
phase compared to single treatment with doxorubicin (figure 3C). 
Discussion
The aim of this work was to show tumor responses to NVP-AEW541 in breast carcinoma 
cell lines of different clinical subtypes and test the combination with conventional 
systemic drugs. Selection of our cell lines was based on the histologic parameters which 
direct current selection of breast cancer therapy. The SKBR3 cell line represents HER2-
overexpressing breast tumors. MCF7 and T47D represent luminal hormone receptor-
positive breast cancer. Because MCF7 is strongly ER positive and HER2 negative, it 
may represent luminal A breast cancer, whereas T47D might represent luminal B breast 
cancer, because this cell line is ER positive and weakly HER2 positive. No cell line 
representing the triple negative or basal-like subtype was included in the present study. 
Best responses to IGF-1R-directed therapy are anticipated in high IGF-1R-expressing 
cells. However, the magnitude of effect of NVP-AEW541 in our experiments was not 
proportional to IGF-1R membrane expression. T47D cells, although expressing high 
levels of IGF-1R, showed resistance to IGF-1R-targeted drugs in comparison to high 
IGF-1R-expressing MCF7 cells, and was even less sensitive to NVP-AEW541 than 
low IGF-1R-expressing SKBR3 cells. These data may indicate that luminal B type 
tumors may be resistant to IGF-1R-targeted therapy in contrast to the luminal A type, 
irrespective of IGF-1R expression. 
NVP-AEW541 induces G-0/G-1 arrest in breast cancer cell lines grown in monolayer 
and inhibits proliferation, while apoptosis is not a prominent effect. Comparison of 
previous studies suggests more dramatic effects of IGF-1R inhibition in anchorage-
independent growth conditions (anoikis) compared to monolayer (proliferation) [25]. 
Our results in monolayer culture are consistent with the results of others by IGF-1R 
inhibition with alphaIR-3 [26].
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Figure 6. The effect of alphaIR-3 and NVP-AEW541 on phosphorylated IGF-1R and downstream 
AKT and ERK in serum-starved MCF7 (A) T47D (B) and SKBR3 (C) cells. 1: untreated cells; 2: IGF-
1 (100 ng/ml) for 5 min; 3: NVP-AEW541 (2.5 µM) for 10 min followed by IGF-1 (100 ng/ml) for 
5 min; 4: NVP-AEW541 (2.5 µM) for 6 h followed by IGF-1 (100 ng/ml) for 5 min; 5: alphaIR-3 (1 
µg/µl) for 10 min followed by IGF-1 (100 ng/ml) for 5 min; 6: alphaIR-3 (1 µg/µl) for 6 h followed by 
IGF-1 (100 ng/ml) for 5 min; Actin was used as a control for loaded protein concentrations.
Figure 7. The effect of doxorubicin and NVP-AEW541 on MCF7 (left), T47D (center) and SKBR3 
(right). Lanes: 1: untreated cells; 2: doxorubicin 0.5 µM 24 h; 3: 2.5 µM NVP-AEW541 followed by 
doxorubicin 0.5 µM 24 h; 4: doxorubicin 0.5 µM 24 h followed by 2.5 µM NVP-AEW541
We further show IGF-1R down-regulation by NVP-AEW541. IGF-1R antibodies 
are known to cause receptor down-regulation by internalization and degradation of 
the receptor by endocytosis [27-29]. Mechanisms by which receptor down-regulation 
occurs with tyrosine kinase inhibition of the receptor are as yet unclear. Receptor down-
regulation may contribute to the effects of therapeutic drugs on IGF-1R functioning, 
or may be merely a manifestation of a low proliferative state. 
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Our assays may indicate the latter, as we saw a similar effect on receptor down-regulation 
occurring at a later timepoint in untreated cells. Cells might well have been beyond 
their exponential growth phase at this later timepoint. AKT and ERK are both critical 
components of two respective major downstream proliferation and survival pathways 
of IGF-1R. In the presence of IRS1, IGF-1R signaling through phosphorylation of 
receptor phosphorylation sites induces recruitment and phosphorylation of IRS 
proteins, resulting in recruitment of p110, the catalytic subunit of PI3K, generation 
of phosphoinositol trisphosphate, and subsequent activation of AKT. The IRS1/PI3K/
AKT pathway is considered a preferential pathway of IGF-1R [30]. The second major 
survival pathway results from Rat sarcoma (RAS) signaling after recruitment of adaptor 
proteins to the activated IGF-1R and subsequent activation of transcriptional programs 
downstream of the ERKs, also referred to as the MAPK pathway. The requirement for 
activation of AKT or ERK in IGF-1R-mediated (survival) signals appears to be context 
dependent and has not yet been fully determined. Moreover, other receptor tyrosine 
kinases, such as HER2 and EGFR, share the same downstream signal transduction 
[16]. Our breast cancer cell lines of different clinical subtypes exhibited differential 
phosphorylation levels of both AKT and ERK in low serum conditions, upon stimulation 
with IGF-1, and blocking by NVP-AEW541, respectively. A previous study comparing 
MCF7 to T47D cells, expressing almost identical IGF-1R levels, has suggested that 
reduced sensitivity/resistance to NVP-AEW541 in T47D cells is determined by a 
lack of IGF-1R signaling through downstream proteins IRS1 and PI3K/AKT [22]. In 
contrast to this report, we found AKT phosphorylation by IGF-1 stimulation both in 
MCF7 and T47D cells, as well as down-regulation of phosphorylated AKT in both cell 
lines in response to NVP-AEW541. Caution should be exercised with comparing data 
of the same putative cancer cell lines yet cultured in separate laboratories, as these may 
differ considerably due to genetic instability and digression. However, our data seem to 
confirm that T47D cells do not depend on the IRS1/PI3K/AKT pathway for survival 
and proliferation, whether or not the pathway is functional, causing resistance to NVP-
AEW541. Contrary to expectations, in SKBR3 cells, levels of constitutively activated 
AKT, which did not further change upon IGF-1 stimulation, were nonetheless down-
regulated in response to NVP-AEW541. This may suggest constitutively activated 
IGF-1R, or, more likely, non-IGF-1R-specific effects of NVP-AEW541. Non-IGF-
1R-specific effects of NVP-AEW541 are supported by reported dosage-dependent 
specificity of the drug. The IC₅₀ of inhibition of IGF-1R autophosphorylation by NVP-
AEW541 is much lower (0.086 µM) than the effective doses in our study (2.9-5.6 µM). 
The reported IC₅₀ of inhibition of IR autophosphorylation by NVP-AEW541 is 2.3 
µM [17]. Although we did not exclude co-targeting of both IGF-1R and IR by NVP-
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AEW541 in our study, the measured phosphorylated receptor levels by an antibody 
directed against both phosphorylated forms of IGF-1R and IR showed no activity 
in SKBR3 cells. Another possibility may be that heterodimeric or heterotrimeric 
complexes of IGF-1R with HER1-4 receptors are formed and co-targeted by NVP-
AEW541 [15, 31]. Several lines of evidence suggest synergistic augmentation of 
trastuzumab effects by NVP-AEW541 in HER2-positive breast cancer with or without 
acquired trastuzumab resistance [19, 20]. IGF-1 induced ERK phosphorylation in 
MCF7 cells was only partly blocked by NVP-AEW541, possibly due to remaining 
activity of non-tyrosine kinase domains, such as serine clusters. Constitutive levels 
of pERK in SKBR3 and T47D cells were not blocked, suggesting constitutive ERK 
activation independently of the IGF-1R. Whereas combinations of NVP-AEW541 
with cytostatic agents had additive effects in MCF7 and SKBR3 cells, comparable to 
responses seen by other study groups [32-34], we found an antagonistic effect of the 
combination of NVP-AEW541 with doxorubicin in T47D cells. Varying sequences of 
NVP-AEW541 and doxorubicin administration did not alter the antagonistic effects 
in our hands. Timing of IGF-1R-targeted therapy by antibodies has previously been 
shown to affect responses to chemotherapy both in vitro and in vivo [35]. The optimal 
sequence proved to be doxorubicin followed by anti-IGF-1R antibody. Clearly, these 
results do not apply to IGF-1R tyrosine kinase inhibition in the same way. This could 
be explained by different time-effect curves of antibodies vs. tyrosine kinase inhibition, 
for instance NVP-AEW541 blocked IGF-1R activity more quickly than the antibody 
alphaIR-3. No plausible explanation was found for the antagonistic effect in T47D cells. 
Up-regulation of phosphorylated ERK levels after single treatment with doxorubicin, 
which NVP-AEW541 did not inhibit, suggests ERK up-regulation occurs downstream 
of the IGF-1R, and upstream inhibition may therefore be in vain. On the other hand, 
such a mechanism is unlikely to cause contrary effects. Cell cycle distribution analysis 
suggests additive effects of doxorubicin and NVP-AEW541. Consistent with previous 
reports, doxorubicin alone arrests cells in the G-2/M phase by interacting with DNA 
synthesis and transcription by DNA intercalation [36]. Due to the NVP-AEW541 
induced G-0/G-1 arrest, G-2/M arrest by doxorubicin is reduces, but the overall 
S-phase fraction is not altered. The biological response to IGF-1R inhibitors in cancer 
cells is diverse and may be dependent on multiple factors, according to the literature. 
Many studies have indicated not only IGF-1R expression, but interaction with related 
receptors, such as estrogen receptor, HER2 family of receptors and the IR, as well as 
functionality of downstream proteins, such as IRS1 and -2, and AKT, on determining 
functional responses of the IGF-1R and sensitivity to anti-IGF-1R agents. Our study 
confirms the results of many other studies and we see conventional results in a majority 
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of our cell lines and drug combinations. However, more problematic issues arise when 
we look in further detail into the minority of unexplained contrary effects. Neither in our 
study, nor in the existing literature, did we find satisfactory clarifications of unpredicted 
responses, which raises the possibility of unexpected and contrary effects in clinical 
use. Analogous to the cell lines MCF7 and T47D, responses to IGF-1R inhibitory 
drugs may be unpredictable in patients with high IGF-1R-expressing and hormone-
responsive breast cancer. It also may be possible that combining chemotherapy with 
IGF-1R tyrosine kinase inhibitors may be beneficial in certain patients in combination 
with certain chemotherapeutic drugs, but disadvantageous in others. Tyrosine kinase 
inhibitors are generally considered less specific compared to monoclonal antibodies 
and may be more prone to having upredictable clinical effects. In order to address 
such issues, we believe new techniques and biomarkers are needed to overcome the 
shortcomings of the studies to date. 
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Summary and future perspectives
Breast cancer is a heterogeneous disease with differences in sensitivity to drug treatment 
and outcome between histological and molecular subtypes. Hormone and HER2 
receptor expression direct custom-made treatment options. Endocrine therapies, such as 
tamoxifen and aromatase inhibitors, are effective only among patients with tumors that 
express estrogen receptor and/or progesterone receptor. Treatment with trastuzumab, 
the first clinically approved antibody against HER2, combined with cytotoxic drugs 
has resulted in clinical benefit in patients with local or advanced HER2-overexpressing 
breast cancers. Triple negative breast carcinomas, characterized by absence of ER, PR 
and HER2 expression, on the other hand, lack a scaffold for conventional endocrine 
and targeted therapies and exhibit worse clinical outcomes. 
Accumulating evidence suggests that monotherapy with a target-specific drug may be 
insufficient to address the inclination of tumors to rely on more than one defective 
or interacting signaling pathway, causing resistance to therapy and tumor progression 
under these therapies, sometimes after initial good response. Therefore, new targets are 
needed and the insulin-like growth factor 1 receptor (IGF-1R) could represent one of 
such new potential targets. 
In chapter 2 the established evidence for IGF-1R involvement in malignant behaviour 
of tumor cells is reviewed and potential for introduction of IGF-1R targeted drugs 
in cancer treatment is explored. IGF-1R contribution to tumor progression has been 
confirmed in a wide range of tumors, both in vitro and in vivo. In  breast carcinomas, 
39–93% of tumors show expression of high levels of IGF-1R. IGF-1R expression in 
breast cancer is correlated with hormone receptor expression and well differentiated 
tumors in most studies. Amplification, however, or increased levels of IGF-1R activation 
has not been shown. Although correlations with clinical or pathological parameters are 
infrequently found, IGF-1R may represent a common target in a spectrum of tumor 
types, considering the wide range of tumors that are sensitive to IGF-1R blockade 
by antibodies and TKIs in vitro and in vivo. Early phase clinical trials of IGF-1R 
antibodies showed no dose limiting (diabetic) toxicities and early evidence of clinical 
activity was shown in various tumor types. Less data on clinical effects of IGF-1R TKIs 
were present,  and more overlap with IR targeting is anticipated in this group of drugs, 
due to less specificity over IR. Biomarkers are urgently needed to predict responses and 
select patients who may benefit from IGF-1R targeted therapy.
The results presented in chapter 3 contribute to development of biomarkers that 
may predict responses and select patients who may benefit from IGF-1R targeted 
107
therapy in breast cancer. In this study, IGF-1R expression by immunohistochemistry 
was investigated in a consecutive cohort of 429 female patients with invasive ductal 
carcinomas (IDCs) of the breast, the most prevalent histological subtype. Patients with 
tumors expressing cytoplasmic IGF-1R showed better disease-free and breast-cancer 
specific survival rates. This effect was most prominent in ER positive tumors. Special 
attention was put on a subgroup of triple negative IDC and to enlarge the TN-IDCs 
cohort, we combined our dataset of 51 TN-IDC tumors with 64 TN-IDCs with similar 
clinicopathological parameters. In the combined series of 105 TN-IDCs cytoplasmic 
IGF-1R expression was associated with a shorter DFS, also when combined in a 
multivariate model, including well-known prognostic factors. 
Based on these data and previous reports, it could be hypothesized that well 
differentiated, ER-positive breast cancers retain physiological growth control by ER 
and IGF-1R signaling, while in ER-negative carcinomas IGF-1R expression confers 
primarily metastatic capacities. ER-positive carcinomas represent a large subclass of 
breast carcinomas with presumably a distinct biology and an excellent prognosis. 
Because IGF-1R and hormone receptors closely interact, a combination of hormonal 
therapy with IGF-1R drugs may help to block all mitogenic hormonal responses. 
Also, as modulations of the IGF-1R system have been implicated in development 
of resistance to endocrine therapies, IGF-1R directed therapy might overcome or 
prevent development of hormone therapy resistance. Therefore we suppose that IGF-
1R directed therapy may complement therapy for hormone receptor positive breast 
cancers, in particular in case of constitutive or acquired resistance to endocrine therapy. 
In triple negative patients, inhibition of the IGF-1R-mediated signaling is likely to 
have a clear beneficial effect on its own as has been shown by others in a mouse model.
As IGF-1R cellular signaling is solidly implicated in tumor progression and high 
circulating IGF-1 levels are identified as a risk factor for developing breast cancer, 
circumstantial evidence is provided that endocrine IGF-1 is involved in tumor 
progression. Final proof however is lacking. In chapter 5 we explored the effect of IGF-
1 and IGFBP-3 blood levels on overall survival and occurrence of second primary breast 
tumors in breast cancer patients, and searched for reproductive and lifestyle factors that 
could modify this risk. Patients were accrued from six hospitals in the Netherlands 
between 1998-2003. Total IGF-1 and IGFBP-3 were measured in 584 plasma samples 
of breast cancer patients. High IGFBP-3 levels were related to better overall survival, 
but this relationship lost statistical significance in the multivariate cox regression model. 
High IGF-1 levels were related to worse overall survival in patients receiving hormonal 
therapy in a multivariate cox regression model including standard prognostic variables. 
These data at least indicate that higher IGF-1 levels, and as a consequence most likely 
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IGF-1-induced signaling, are related to less favorable overall survival of hormone 
receptor positive breast cancer patients receiving endocrine treatment. The role of IGF-
1 serum levels in hormone receptor negative breast cancer remains to be elucidated. 
Our study may have suffered from a selection bias in favor of patients with a mild course 
of disease as patients were included into the study during their regular follow-up after 
initial diagnosis and treatment. Also, estrogen receptor status of tumors itself was not 
available in this database, and caution is warranted with the interpretation that high 
IGF-1 levels are related to worse overall survival in hormone receptor positive patients 
sec. Rather, effective antiestrogen treatment for hormone receptor positive tumors 
lowers IGF-1 concentrations and persistent high IGF-1 levels in thus treated patients 
may correlate with failure or resistance to endocrine treatment. Indeed, modulations 
of the IGF-1 axis have been implicated in development of resistance to endocrine 
therapies. Future investigations should be directed at exploring if high IGF-1 levels 
or an absent or modest drop in IGF-1 levels in response to hormonal treatment are a 
measure of failure of endocrine therapy. Interventions aimed at reducing circulating 
levels of IGF-1 may improve outcome of endocrine therapies for breast cancer.
Epidemiological studies, such as presented in chapter 5, benefit from unbiased blood 
specimens collected with minimal cost and effort of blood collection and storage. In 
chapter 4 we conducted a feasibility study, and evaluated the stability of IGF-1 and 
IGFBP-3 in whole blood samples stored at room temperature to justify delays in blood 
processing. For that purpose, total IGF-1 and IGFBP-3 levels were measured in EDTA 
(n=12), heparin (n=12) and serum (n=10) samples of healthy volunteers after blood 
processing delays up till 14 days. In serum and heparin, however, IGF-1 increased 
over time of delayed processing and IGFBP-3 levels tended to decrease starting from 
early time-points. IGF-1 and IGFBP-3 levels, however, appeared stable in whole blood 
collected in EDTA tubes at room temperature up till 7 days, allowing a delay in blood 
processing to reduce costs in large multi-center studies. 
IGF-1R targeted antibodies as well as tyrosine kinase inhibitors (TKI) have been 
developed and several antibodies have by now proceeded to phase I and II clinical 
trials. TKIs inhibit receptor activation by directly binding to and blocking the catalytic 
kinase domain, these small molecules are generally considered less specific compared to 
monoclonal antibodies and may be more prone to unpredictable clinical effects. As the 
kinase domains of IGF-1R and IR are nearly identical, it is hard to achieve specificity 
for IGF-1R over IR. In chapter 6 responses to the highly specific IGF-1R tyrosine 
kinase inhibitor NVP-AEW541, alone and in combination with conventional systemic 
drugs, were tested in different clinical subtype breast cancer cell lines, expressing 
contrasting levels of ER, HER2 and IGF-1R. Activation status of the IGF-1R and 
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downstream proteins Akt and Erk and cell cycle distribution were determined under 
several experimental conditions. NVP-AEW541 reduced proliferation in all tested cell 
lines in a dose-dependent manner and changed cell cycle distribution significantly with 
a reduction of the S-phase fraction. The magnitude of effect of NVP-AEW541 was 
not proportional to IGF-1R membrane expression of each of the cell lines. Synergistic 
cytotoxic effect was seen when NVP-AEW541 was combined with trastuzumab in 
the hormone receptor positive T47D cell line, which expresses high levels of IGF-1R 
and intermediate levels of HER2 and EGFR. In this same cell line, NVP-AEW541 
combined with doxorubicin had antagonistic effects, irrespective of treatment sequence. 
All other treatment combinations revealed additive effects. As expected, NVP-AEW541 
downregulated phosphorylation of IGF-1R and its downstream proteins Akt and Erk. 
Notwithstanding a slight upregulation of phosphorylated Erk in T47D cells, which was 
not inhibited by NVP-AEW541, this unexpected antagonistic effect could not fully be 
accounted for, neither for the disproportional effects in low IGF-1R expressing tumor 
cells. We hypothesise that these unpredicted responses may reflect varying degrees 
of dependency on pathways downstream of the IGF-1R such as IRS-1/PI3K/Akt, 
interaction of IGF-1R with human epidermal growth factor (HER) receptors or non-
IGF-1R specific effects of NVP-AEW541. The biological response to IGF-1R tyrosine 
kinase inhibitors in cancer cells is diverse and may be dependent on multiple factors. 
The less-specific nature of IGF-1R TKIs may lead to undesirable, e.g. insulin-related, 
side-effects but may as well in the end prove to be the desired multi-tasking weapon, 
destroying not only the direct target but interfering with possible escape and survival 
mechanisms of tumor cells at the same time. In an attempt to further dissect IGF-1R 
pathways and linkage with other signal transducing proteins, we performed several 
high trough-put kinome analysis experiments. Unfortunately, the results of these efforts 
were not suitable for publication due to immaturity of the utilized technique. We think 
innovative techniques currently evolving such as multiplex kinome profiling do have 
great potential to reveal relevant signaling networks and predict tumor responses. 
During the last years, the IGF-1R antibodies figitumumab and cixutumumab have 
been studied in Phase I and II clinical trials. These drugs are well-tolerated as single 
agent and modest single activity has been shown in Ewing’s sarcoma. However, progress 
has substantially been hampered by discouraging lack of survival advantage in a Phase 
III randomized trial of carboplatin and paclitaxel with figitumumab in first-line for 
metastatic NSCLC. 
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The insulin-like growth factor receptor system has intrigued many by discoveries of 
involvement in energy balance, growth and thriving, and life span. Interest of the 
role of insulin-like growth factors in cancer began more than three decades before 
and reached a peak in the 1990s. After initial excitement, the subject temporarily lost 
its appeal when newly acquainted insights could not be brought into the clinic until 
humanized therapeutic antibodies engineering techniques had matured. The availability 
of monoclonal antibodies and small molecules that block the insulin-like growth factor 
1 receptor in recent years has fuelled in-depth molecular research on IGF-1R signaling 
in cancer and advanced clinical trials. Now again, the IGF-1R raises a major challenge, 
this time to succeed in fine-tuning of indications for IGF-1R directed therapy. There are 
several causes underlying this challenge that need to be addressed and not surprisingly 
one of them comes down exactly on the ‘complex interrelationships’ of IGF-1R already 
foreseen in the 1976 PNAS paper. Also, the comprehensive nature of the IGF-1R/
insulin system coupled with modest overall responses on IGF-1R antagonists may 
warrant a new style of evidence-based medicine in clinical oncology. 
The body-wide availability of IGF-1R system components to both normal and tumor 
cells and a tight linkage to growth and metabolism of normal and tumor cells alike, 
provide scarce distinguishing capacity for currently available biomarkers to direct 
IGF-1R therapy. Pathologic mutations or overexpression are not a prominent clinical 
feature of IGF-1R involvement in cancer. This is a major barrier in the design of 
conventional randomized controlled trials with sufficient statistical power to guide 
clinical introduction of anti-IGF-1R therapies. Conversely, the comprehensive 
nature of IGF-1R is an open invitation to tumors of any sort and kind to use its 
proliferating and anti-apoptotic properties as an escape and survival mechanism. This 
is repeatedly highlighted by demonstration of the reversal of drug tolerance to, among 
others, endocrine therapy, HER2 and EGFR inhibitors by IGF-1R antagonists. The 
interrelationships of IGF-1R with steroid hormones and growth factor receptors, as 
well as metabolic pathways, are multiple and diverse, supporting many potential escape 
routes. Formation of heterodimers of IGF-1R with e.g. HER2, EGFR and insulin 
receptor may preserve downstream signaling under antibody monotherapy. Common 
pathways are shared between several other RTKs. IGF-1R translocation to cytoplasm 
and nucleus may add further complexity to co-functioning with intracellular proteins 
and gene regulation. These factors may have contributed to failure of the first phase III 
trial with IGF-1R antibody (addition of figitumumab to paclitaxel plus carboplatin in 
NSCLC) showing no benefit at the interim analyses. Disappointingly, this has led to 
discontinuation of the entire development program of the furthest developed IGF-1R 
antibody in the clinical setting (Yee D, JNCI 2012;104:975-981).   
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In breast cancer, the interaction with currently known therapeutic targets, steroid 
receptors and HER2, has received much attention. Our study support approaches of 
combining IGF-1R directed antibodies with endocrine therapy and the use of IGF-1R 
therapy in triple negative breast tumors. A first randomized controlled trial conducted in 
posmenopausal women with hormone-receptor positive metastatic or locally advanced 
breast cancer combining an IGF-1R antibody with aromatase inhibitors, however, did 
not result in an improvement in progression-free survival (Kaufmann PA, Ferrero JM, 
Bourgeois H et al. Cancer Research 2010;70:s1-4). 
Drugs targeting the IGF-1R have shown discouraging results in large randomized 
clinical trials. IGF-1R antibodies have shown to be no weapon of mass destruction, 
but maybe they should rather be seen as a strategic intelligence force. Given the 
complex interrelationships of the IGF-1R system and lack of known biomarkers to 
predict response, development of IGF-1R targeted therapy will benefit from expansion 
of the capacity to monitor molecular behaviour of individual tumors more closely. 
Not large randomized controlled trials, but complementation of trials with advanced 
molecular biology techniques, bioinformatics and nuclear tracing techniques showing 
the dependencies on molecular pathways of individual tumors will do justice to the 





Dit proefschrift gaat over de rol die Insulin-like Growth Factor-1 (IGF-1) en zijn 
receptor (IGF-1R) spelen bij de ontwikkeling en groei van borstkankercellen en over 
de invloed die zij zouden kunnen hebben op de ernst van het ziektebeloop. Ten slotte, 
over de vraag of bepaalde borstkankertypen kunnen worden behandeld door IGF-1R 
als doelwit van de behandeling te gebruiken.
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Borstkanker
Bij borstkanker gaan cellen in het borstweefsel zich ongebreideld delen, waardoor een 
gezwel of tumor ontstaat. In het beginstadium woekeren tumorcellen in de melkgangen 
en klierkwabben van de borst. Maar als kwaadaardige cellen niet worden tegengegaan, 
groeien ze dwars door andere weefsels heen en kunnen zij zich in een later stadium 
zelfs verspreiden via de lymfebanen en bloedvaten door het hele lichaam. Dan is er 
sprake van uitzaaiingen. Er zijn verschillende typen borstkanker gedefinieerd. In dit 
proefschrift hanteren we de indeling waarbij borstkanker HER2-positief kan zijn, 
hormoon receptor-positief, triple-positief (HER2 en hormoon receptor positief ) of 
triple-negatief (geen HER2 of hormoon receptoren gevonden in het tumorweefsel). 
Deze classificaties geven informatie over hoe de specifieke tumor zich gedraagt en welke 
behandeling het meest effectief kan zijn. 
Celdeling en IGF-1
IGF-1 speelt een cruciale rol in het lichaam bij de celdeling, groei en stofwisseling. 
IGF-1 is een eiwit dat in structuur en werking lijkt op insuline. Maar waar insuline 
met name de energie-huishouding beinvloedt, regelt IGF in dit systeem de celdeling en 
bepaalt mede het karakter van de cel of het organisme. Bij honingbijen bijvoorbeeld, 
is het een eiwit in dit insuline-achtige systeem dat bepaalt of de vrouwelijke larf een 
werkbij of een koningin wordt. 
Receptoren zijn eiwitten die zich in de cel of op het celoppervlak bevinden. Receptoren 
ontvangen signalen van buiten de cel. Een eiwit, hormoon, medicijn of andere chemische 
stof kan zich aan de receptor binden. Zo’n stof geeft een signaal aan de cel af om iets te 
doen: delen, sterven of andere substanties toestaan om de cel binnen te dringen of te 
verlaten. Er zijn veel verschillende soorten receptoren. Specifieke moleculen verbinden 
zich aan specifieke receptoren. Zo reageert de IGF-1 receptor op de aanwezigheid 
van IGF-1 in de bloedbaan. Tumorcellen maken ook gebruik van dergelijke signalen 
via receptoren. Sommige tumoren maken een abnormaal grote hoeveelheid van een 
bepaalde receptor aan, dit wordt ‘overexpressie’ genoemd. 
IGF-1 en borstkanker
In verschillende onderzoeken is een verband gevonden tussen de aanwezigheid van 
IGF-1 en de ontwikkeling van kwaadaardige tumoren. Dat verband is bijvoorbeeld 
aangetoond bij menselijke dwergen en dwergknaagdieren. Zij produceren minder 
groeihormoon, waardoor er ook minder IGF-1 in het lichaam aanwezig is. Zij leven 
lang en ontwikkelen minder vaak kanker. Ook bij muizen blijkt dit verband zo te 
bestaan. Bij muizen met een tekort aan IGF-1 groeien tumoren minder snel en zijn 
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tumoren minder geneigd om uit te zaaien. Een overschot aan IGF-1 leidt tot een 
abnormaal hoge celdeling en het makkelijker ontstaan van tumoren.
Al in 1976 wordt vastgesteld dat het insuline en het insuline-achtige systeem betrokken 
is bij de ontwikkeling van borstkankercellen. Het artikel waarin over dit onderzoek 
werd gerapporteerd, beschreef hoe onderzoekers de groei van een hormoongevoelige 
borstkankercellijn (MCF7) stimuleerden met insuline. Diezelfde cellijn is gebruikt bij 
experimenten in het kader van dit proefschrift. In 1984 ontdekten onderzoekers dat 
IGF-1 een belangrijk signaaleiwit is bij de groei van borstkankercellen. Vijf jaar later 
werd de IGF-receptor, IGF-1R, geïdentificeerd in weefsels van borsttumoren. Pas in 
de jaren negentig werd er een manier gevonden om zulke receptoren, zoals de IGF-
1 receptor, bij mensen te blokkeren door het toedienen van voor de mens geschikt 
gemaakte antilichamen. De ontwikkeling van het antilichaam tegen de HER2 receptor 
(trastuzumab of Herceptin) was een doorbraak in de behandeling van borstkanker.
Voor hormoonreceptor-positieve en HER2-positieve borstkankertumoren bestaan 
gerichte behandelingen. Bij patiënten met hormoonreceptoren is behandeling met de 
anti-hormonale medicijnen tamoxifen en aromataseremmers effectief. Behandeling 
met het antilichaam trastuzumab in combinatie met chemotherapie wordt gebruikt 
bij patiënten met borstkankertumoren met HER2 overexpressie. Voor triple-negatieve 
borstkankertumoren is er geen gerichte behandeling mogelijk, omdat dit type 
borstkanker geen aangrijpingspunten van bekende receptoren biedt. Daarnaast reageert 
dit type borstkanker vaak minder goed op standaard chemotherapie. De prognose 
van dit type borstkanker is dan ook slechter dan van andere borstkankersoorten. 
Uit onderzoek blijkt echter ook dat veel kwaadaardige tumoren gebruikmaken van 
verschillende defecte signaleringen via (mogelijk) meerdere receptoren. Deze tumoren 
blijken resistent voor de behandeling door een alternatieve receptor of signalering te 
gebruiken. Het is daarom belangrijk om nieuwe doelwitten te vinden in de strijd tegen 
borstkanker. IGF-1R zou zo’n nieuw doelwit kunnen zijn.
Kleine moleculenmedicatie
De hernieuwde belangstelling voor IGF-1R eind jaren negentig viel samen met de 
introductie van zogenaamde ‘kleine moleculenmedicatie’ bij kankerbestrijding. Deze 
medicatie werkt niet via binding van een antilichaam aan een receptor, maar het zijn 
enzymremmers die de receptor rechtstreeks beïnvloeden via de signaaleiwitten (tyrosine 
kinases) die aan receptoren verbonden zijn. Bij de start van het onderzoek in het kader van 
dit proefschrift, waren er niet alleen tegen IGF-1R gerichte antilichamen ontwikkeld, 
maar ook dergelijke enzymremmers tegen IGF-1R: IGF-1R tyrosine kinase remmers. 
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Er was echter weinig bekend over welke tumoren zouden reageren op medicijnen 
tegen de IGF-1R en welke patiënten hier baat bij zouden hebben. In verschillende 
soorten tumoren hebben onderzoekers aanwijzingen gevonden dat groeisignalen van 
IGF-1 en IGF-1R de groei en kwaadaardigheid van deze tumoren beïnvloeden, maar 
bewijzen waren nog niet overtuigend en de samenhang met tumorkenmerken en het 
ziektebeloop waren niet uitgekristalliseerd. IGF-1R blijkt een van de factoren te zijn in 
een goed georganiseerde serie van receptoren die groei stimuleren. Naast IGF-1R zijn 
HER2, oestrogeenreceptoren en de insulinereceptor betrokken bij borstkanker. Om de 
groei van tumoren op lange termijn tegen te gaan, zou het noodzakelijk kunnen zijn 
om meerdere van deze receptoren te bestrijden. 
De nauwe samenhang van de IGF-1R met de insuline receptor is complex. Waar IGF-
1R meer gespecialiseerd is in celgroei en anabole functies, reguleert de insulinereceptor 
vrijwel alleen de energiehuishouding. Toch delen deze receptoren grotendeels dezelfde 
moleculaire opbouw en kunnen hun functies overlappen. Om die reden zijn diabetische 
complicaties te verwachten als IGF-1R remmers worden ingezet. Daarbij komt dat 
IGF-1R-remmers minder effectief zouden kunnen zijn omdat de insuline receptor in 
theorie de functies van een geblokkeerde IGF-1R zou kunnen overnemen.
 
Doel van dit onderzoek
Het doel van dit onderzoek is de samenhang van IGF-1 en IGF-1R met tumorkenmerken 
en het ziektebeloop bij borstkanker vast te stellen en daarnaast de werking van medicijnen 
tegen IGF-1R op borstkankercellen te bepalen. Dit onderzoek werd uitgevoerd bij twee 
grote groepen borstkankerpatiënten en in drie borstkankercellijnen.
Groep 1: De eerste groep bestond uit 429 vrouwelijke patiënten die tussen januari 
1996 en december 2005 behandeld werden voor niet-uitgezaaide borstkanker in het 
Universitair Medisch Centrum Groningen. Van de borstkankertumoren van deze 
patiënten was materiaal aanwezig om IGF-1R, hormoonreceptoren en HER2 te 
kunnen lokaliseren. Daarnaast waren kenmerken van de patiënten en hun ziektebeloop 
en van de tumoren beschikbaar vanuit de ziekenhuisdossiers. Deze gegevens konden 
geanonimiseerd geanalyseerd worden. 
Groep 2: Een tweede groep bestond uit 584 borstkankerpatiënten bij wie bloed was 
afgenomen tijdens een onderzoek naar genetische afwijkingen die tot borstkanker 
leiden. In deze bloedmonsters werd IGF-1 en IGFBP-3 (een bindingseiwit van IGF-
1) bepaald. Van deze patiënten was tevens bekend of zij nog in leven waren en of 
zij nogmaals borstkanker ontwikkeld hadden. Daarnaast hadden deze patiënten 
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vragenlijsten ingevuld over hun levensstijl en voortplanting. Met deze gegevens konden 
we de relatie tussen IGF-1 en IGFBP-3 bloedniveaus en de prognose onderzoeken.
Borstkankercellijnen MCF7, SKBR3 en T47D: In laboratoriumexperimenten 
hebben we de werking van een IGF-1R tyrosine kinase remmer (TKI) onderzocht 
op drie verschillende borstkankercellijnen, die verschillende subtypen borstkanker 
vertegenwoordigen. De cellijn SKBR-3 is HER2 positief, MCF7 cellen zijn 
hormoonreceptor-positieve borstkankercellen en T47D is triple positief. 
De opbouw van dit proefschrift
In hoofdstuk 2 van dit proefschrift wordt een inventarisatie gemaakt van de bestaande 
bewijzen voor de aanname dat IGF-1R een rol speelt bij de groei van borstkankertumoren. 
Eerdere studies beschrijven dat in 39-93% van borstkankertumoren hoge IGF-1R-
niveaus zijn aangetoond. Toch blijkt het lastig om een relatie met tumorkenmerken 
of het ziektebeloop aan te tonen. Veel verschillende typen tumoren reageren in een 
laboratoriumsetting echter goed op blokkade van IGF-1R door antilichamen en 
enzymremmers. IGF-1R lijkt daarom een zinvol doelwit te kunnen zijn in deze tumoren. 
Aanvankelijke aarzelingen om op IGF-1R gerichte medicatie te ontwikkelen werden 
minder groot toen het mogelijk werd geacht om stoffen te ontwikkelen die specifiek 
de IGF-1R remmen en niet tegelijkertijd de insuline receptor, en deze medicijnen 
worden inmiddels ook getest in patiënten. Maar er zijn betere biomarkers nodig om 
te kunnen voorspellen welke patiënten baat kunnen hebben bij tegen IGF-1R gerichte 
behandeling. Waarschijnlijk is het hiervoor belangrijk om te weten welke rol IGF-1R 
speelt in deze tumoren in het netwerk van signaaleiwitten, hormonen en receptoren. 
De resultaten die in hoofdstuk 3 worden gepresenteerd, dragen bij aan de ontwikkeling 
van deze biomarkers. Een van de voorwaarden voor doelgerichte behandeling is een 
meetbare waarde om de gevoeligheid van de tumor voor het medicijn te voorspellen, 
bijvoorbeeld door de hoeveelheid receptoren in de tumor vast te stellen. In dit 
hoofdstuk doen we verslag van de uitkomsten van een onderzoek waarbij in het 
tumorweefsel van een grote groep borstkankerpatiënten de aanwezigheid van IGF-
1R gemeten werd door middel van immunohistochemie. De uitkomsten werden 
vergeleken met de karakteristieken van de patiënten en tumoren, moleculaire markers 
en gegevens over de prognose. De hoeveelheid IGF-1R bleek duidelijk hoger te zijn 
in hormoonreceptor positieve en goed gedifferentieerde tumoren. Over de hele groep 
patiënten genomen bleek IGF-1R expressie samen te hangen met een gunstig beloop 
van de ziekte. Als we echter specifiek in hormoonreceptor positieve en triple negatieve 
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tumoren keken, bleek IGF-1R een tegengesteld verband te laten zien. Terwijl IGF-
1R in hormoonreceptor positieve tumoren vaak voorkwam bij patiënten met een 
gunstig beloop van de ziekte, was de hoeveelheid IGF-1R in triple negatieve tumoren 
juist gerelateerd aan een slechtere prognose. Wellicht is dit verband te verklaren met 
kennis die we uit onderzoek met cellijnen hebben. Hierin wordt gesuggereerd dat 
IGF-1R signalering verschillende effecten kan hebben op celgedrag in verschillende 
typen tumoren. In hormoon receptor-positieve tumoren lijken IGF-1-signalen 
cellen bijvoorbeeld sterk aan te zetten tot woekering door celdeling te stimuleren. In 
hormoon receptor-negatieve tumoren daarentegen zet IGF-1R-signalering met name 
tot migratie aan, wat zou kunnen bijdragen aan het uitzaaien van tumoren. Daarnaast 
zijn er aanwijzingen dat wijzigingen in het IGF-1R-systeem te maken hebben met 
de ontwikkeling van resistentie tegen hormonale therapie. Tegen IGF-1R gerichte 
behandeling in combinatie met hormoontherapie zou kunnen bijdragen aan het sterker 
blokkeren van hormonale reacties die aanzetten tot celdeling en daarnast zou het de 
resistentie tegen hormoonbehandeling wellicht kunnen voorkomen. Ook bij triple-
negatieve tumoren zou op IGF-1R gerichte behandeling wellicht een aangrijpingspunt 
kunnen bieden voor gerichte behandeling die bij deze groep tumoren met een slechte 
prognose ontbreekt. 
Het onderzoek dat in hoofdstuk 4 beschreven is, hebben we uitgevoerd om ons te 
verzekeren van valide meetresultaten van IGF-1 en IGFBP-3 niveaus in beschikbare 
plasmamonsters die gebruikt zouden worden in het onderzoek van hoofdstuk 5. Bij 
grootschalig onderzoek kan om logistieke redenen uitstel optreden bij de verwerking 
van bloedsamples. Daarom hebben we IGF-1 en IGFBP-3-niveaus gemeten in drie 
verschillende soorten bloedmonsters van gezonde vrijwilligers (EDTA-plasma, 
heparineplasma en serum) over een periode van veertien dagen na afname. In het 
EDTA-plasma bleven de IGF-1 en IGFBP-3-niveaus tot zeven dagen stabiel. In 
serummonsters en heparineplasma waren de waarden minder stabiel als de samples met 
uitstel van enkele dagen werden verwerkt. Dit maakt uitstel mogelijk bij het verwerken 
van EDTA-plasmamonsters voor het bepalen van IGF-1 en IGFBP-3 in grootschalige 
onderzoeken.
Hoge IGF-1-niveaus vormen een risicofactor voor de ontwikkeling van borstkanker, 
met name in hormoon receptor-positieve tumoren. Hoofdstuk 5 is een weergave van ons 
onderzoek naar het effect van de aanwezigheid van IGF-1 en IGFBP-3 in het bloed op 
de overleving en optreden van tweede primaire borstkankertumoren. We zochten ook 
naar verbanden met levensstijl- en voortplantingsaspecten die hier een rol bij zouden 
kunnen spelen. Voor dit onderzoek maakten we gebruik van 584 plasmamonsters van 
borstkankerpatiënten die onder behandeling waren geweest in zes Noord-Nederlandse 
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ziekenhuizen in de periode 1998 – 2003. Een hoger IGF-1-niveau bij patiënten met 
hormoonreceptor positieve borstkanker die endocriene therapie krijgen, lijkt te wijzen 
op een minder goede prognose.
Hoofdstuk 6 geeft een weergave van het onderzoek naar de respons van specifieke 
borstkankercellijnen op de IGF-1R tyrosine kinase remmer NVP-AEW541. We 
onderzochten de reactie op NVP-AEW541 in combinatie met conventionele systemische 
medicatie en we onderzochten de veranderingen in de groei, celdelingscyclus en intra-
cellulaire signaleringsnetwerken van IGF-1R. In alle cellijnen bleek dat NVP-AEW541 
de celdeling tegenging, maar het effect was niet in alle cellen evenredig met de expressie 
van IGF-1R. In T47D, een triple positieve cellijn, was het effect van NVP-AEW541 
niet zo sterk, terwijl deze cellijn wel veel IGF-1R tot expressie brengt. Daarnaast bleek 
deze IGF-1R remmer wanneer deze samen met het chemotherapeutische middel 
doxorubicine werd gebruikt in T47D cellen, de werking van doxorubicine tegen te 
gaan in plaats van de versterken. De reactie op IGF-1R tyrosine kinase remmers in 
kankercellen bleek dus minder goed voorspelbaar te zijn dan gedacht, wat onderstreept 
hoe belangrijk het is om goede aanwijzingen te hebben over de werkzaamheid van IGF-
1R remmers bij specifieke subtypen van tumoren. 
Conclusie
Niet alle dilemma’s rondom het gebruik van IGF-1R remmers in de behandeling 
borstkanker zijn opgelost bij het afronden van dit onderzoek. De IGF-1R komt veel 
voor op normale en tumor cellen en speelt in beide een belangrijke rol bij de celdeling 
en –overleving. Het nadeel hiervan is dat de IGF-1R moeilijk aan te wijzen is als 
een duidelijke pathologische factor bij borstkanker. Daarentegen is het wel duidelijk 
dat IGF-1R juist op deze manier een ontsnappingsmechanisme biedt, vooral bij 
hormoonpositieve tumoren lijkt dit het geval. Het lijkt daarom aantrekkelijk om een 
IGF-1R remmer toe te voegen aan reeds bestaande therapieën. Een onderzoek, waarbij 
een IGF-1R anti-lichaam is toegevoegd aan hormonale therapie bij borstkanker 
patiënten met hormoonpositieve tumoren, liet echter geen gunstige resultaten zien. 
Ook een ander groot onderzoek onder longkanker patiënten, waarbij een IGF-1R anti-
lichaam werd toegevoegd aan de gebruikelijke chemotherapie, heeft teleurstellende 
resultaten opgeleverd. Dit heeft zelfs geleid tot het stopzetten van verdere ontwikkeling 
van dit medicijn door één van de fabrikanten. Waarschijnlijk hebben de complexiteit 
van het IGF-1R systeem met zijn vele componenten en het ontbreken van een 
duidelijk meetbare waarde om de gevoeligheid van de tumor voor IGF-1R remmers 
te voorspellen bijgedragen aan het mislukken van de eerste experimenten. Omdat de 
IGF-1R TKI’s minder gericht zijn dan IGF-1R anti-lichamen, kunnen ze ongewenste 
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(insuline-gerelateerde) bijwerkingen hebben, maar zouden ze uiteindelijk ook het 
ultieme wapen kunnen zijn, dat niet alleen het directe doelwit vernietigt, maar ook 
de mogelijke ontsnappings- en overlevingsmechanismen van tumorcellen tegengaat. 
Belangrijk voor vervolgonderzoek is dat moderne technieken waarmee het mogelijk 
wordt om complexe relaties tussen verschillende receptoren en signaaleiwitten te 
analyseren gebruikt worden  bij het ontwikkelen en introduceren van nieuwe middelen 
zoals IGF-1R remmers.  
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You can’t connect the dots looking forward; you can only connect them looking backwards
Steve Jobs, Stanford Commencement Address, 2005
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